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Zusammenfassung 
 
Das Melanom ist die tötlichste Hautkrebsart und ist in einem fortgeschrittenen 
Stadium schwierig zu behandeln. Fibroblasten Wachstumsfaktoren (FGF1-23) und 
deren Rezeptoren (FGFR1-4) sind beteiligt an Tumorwachstum, Angiogenese und 
Überleben von malignen Zellen bei verschiedensten Tumorarten. Eine krebs-
stimulierende Rolle im speziellen beim Melanom, wurde für die Wachstumsfaktoren 
FGF-1 (aFGF) und FGF-2 (bFGF), sowie den FGF Rezeptor FGFR-1 nachgewiesen. 
Außerdem wurde eine Korrelation, zwischen der FGFR-4 Protein Expression und 
dem Überleben von Melanom-Patienten, beschrieben. Es wird auch angenommen, 
dass der kürzlich identifizierte Arg/Gly Polymorphismus von FGFR-4, die Progression 
und Zell Migration von einigen Krebsarten stimuliert. 
Ziele: Die Ziele waren (A) eine Evaluierung des Potenzials von FGF-Rezeptoren als 
therapeutische “Targets” in der Melanombehandlung, und (B) die Untersuchung des 
FGFR-4 Arg/Gly Polymorphismus und seine möglichen Auswirkungen auf Melanom 
Zelllinien. 
Methoden: Die Methoden umfassten, (I) eine Expressionsanalyse von allen FGF-
Rezeptoren, sowie deren verschiedenen Isoformen und allen 22 humanen FGF-
Liganden mittels Standard PCR und qRT-PCR, (II) Analyse der zellulären Effekte 
durch Blockierung des FGFR Signals mittels dominant-negativer Rezeptor 
Konstrukte, (III) Untersuchung der Effekte von FGFR Blockierung auf das 
Tumorwachstum In Vivo mittels Xenotransplantationsexperimente in SCID Mäusen, 
(IV) Analyse der Auswirkungen von niedermolekularen FGFR Inhibitoren, im 
Vergleich zu FGF-2 Stimulation, auf den FGFR Signalweg, (V) Untersuchung von 41 
Melanomproben hinsichtlich FGFR-4 Arg/Gly Expressionsmuster und Vergleich mit 
der Progressionsstufe des Tumors, (VI) Analyse der Effekte des FGFR-4 Arg Allels 
auf die Zellmigration und Proliferation. 
Resultate: Die Expressionsanalyse zeigte, dass der FGFR-1 und der FGFR-4 in 
nahezu allen Melanom Zelllinien stark exprimiert werden, im Vergleich zu FGFR-2 
und FGFR-3. Nimmt man jedoch primäre Melanozyten als Referenz, so scheint 
ausschließlich die Expression von FGFR-4 und FGFR-2 hinaufreguliert, während die 
Expression von FGFR-1 auf einem hohen Niveau bestehen, und FGFR-3 
unverändert niedrig, bleibt. Im Allgemeinen, ist die Expression der FGF-Rezeptoren 
und deren Isoformen sehr heterogen ausgefallen, vergleicht man das 
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Expressionsmuster der Zelllinien untereinander. Verkürzte FGFR Isoformen und 
Isoformen ohne Transmembrandomäne, wurden nur in rund der Hälfte der 
untersuchten Zelllinien nachgewiesen.  
Betrachtet man die Expression der FGF Liganden, so wurde gezeigt, dass FGF-2 in 
allen untersuchten Melanomzelllinien sehr stark exprimiert wird, im Gegensatz zu 
primären Melanozyten. FGF-5 wurde in der Mehrheit der Zelllinien (90%) exprimiert, 
während die Expression von FGF-18 in ungefähr 40% hinaufreguliert war und das 
Expressionsniveau von FGF-17 und FGF-8 in allen Zelllinien durchwegs niedrig 
ausfiel.    
Eine Inhibierung der FGF-Rezeptoren durch dominant-negative FGFR Konstrukte 
zeigte, dass eine Blockierung des FGFR-1 Signalweges ein vielversprechender 
therapeutischer Ansatz beim Melanom ist. Eine „In Vitro“ Inhibierung wurde mittels, 
Proliferations-, Klonogenizitäts- und Soft Agar- Experimente, getestet. Resultate 
wurden anschließend „In Vivo“, durch  Xenotransplantation von Melanomzellen in 
SCID Mäuse, bestätigt. Weiters wurde gezeigt, dass eine Inhibierung des FGFR-1 
Signalweges in Melanomzellen Apoptose induziert. Dies konnte einerseits durch 
Fluoreszenz-Mikroskopie und Propidiumjodid Färbung verfolgt werden und wurde 
schließlich auch mittels Western-Blot Analyse bestätigt.  
Es wurde gezeigt, dass die Zellvermehrung um ca. 20-40% zunahm, wenn 
Melanomzellen mit FGF-2 stimuliert wurden. Die Intensität stimulatorischer Effekte 
war abhängig vom endogenen Expressionsniveau. Zelllinien mit niedriger FGF-2 
Expression konnten leichter mit zusätzlichem FGF-2 stimuliert werden. Auch die 
Migrationsfähigkeit der Melanomzelllinien konnte um 20-50% erhöht werden, wenn 
FGF-2 oder FGF-5 zugegeben wurde. Die Stärke der Stimulation durch FGF-2 oder 
FGF-5, war auch hier von der Eigenproduktion abhängig. 
Weiters wurde demonstriert, dass der MAPK- und Akt- Signalweg durch FGF-2 
stimuliert werden kann. Aber auch, dass eine vorhergehende Blockierung der FGF-
Rezeptoren, durch „Small Molecule Inhibitors“ (PD166866 und SU5402), diese 
Stimulation verhindert. Eine Blockierung von Signalwegen durch diese Inhibitoren, 
ohne vorherige Stimulation durch FGF-2, konnte jedoch nicht gezeigt werden. 
Eine homozygote Expression des FGFR-4 Gly388 Allels nahm mit zunehmender 
Krebsprogression deutlich ab (Primärtumore: 65%; Metastasen: 42% und maligne 
Effusionen: 20%). Ein Einfluss des FGFR-4 Arg388 Allels auf die Progression im 
Melanom ist daher naheliegend. Bei der Untersuchung von Zellmigration und 
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Proliferation, mittels stabiler Expression des FGFR-4 Arg388 versus Gly388 Allel in 
Melanomzelllinien, wurde gezeigt, dass die Zellproliferation zwischen den Allelen 
unverändert bleibt, die Migration in einer von zwei Arg388 Zelllinien aber 2.5 fach 
zunimmt.  
Schlussfolgerungen: In Vivo, sowie In Vitro, wurde gezeigt, dass die 
Zellproliferation bzw. das Tumorwachstum um 50% reduziert wird, wenn der FGFR-1 
Signalweg durch adenovirale dnFGFR1 Konstrukte inhibiert wird. Als Referenz 
wurden Zellen, anstatt mit dnFGFR1, mit GFP Konstrukten infiziert. Unsere 
Untersuchungen legen eine therapeutische Blockierung des FGFR-1 nahe. Weiters 
kann man daraus schließen, dass das FGFR-4 Arg388 Allel möglicherweise zur 
Progression von Melanomen beiträgt. 
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Abstract 
 
Melanoma is the most deadly cutaneous malignancy and is difficult to treat at the 
advanced stage. Fibroblast Growth Factors (FGF1-23) and Fibroblast Growth Factor 
Receptors (FGFR1-4) are critically involved in tumour cell growth, survival and 
angiogenesis of several tumour types. In melanoma several reports have established 
an oncogenic role of acidic FGF (FGF-1), basic FGF (FGF-2) and FGFR1. Besides, a 
correlation between FGFR-4 protein expression and survival of melanoma patients 
has been described. The recently identified Arg/Gly polymorphism of FGFR-4 is 
suggested to influence cancer progression and cell migration of various tumour types. 
Objectives: The purpose of the study was (A) to evaluate the potential of FGFRs as 
molecular therapy targets for melanoma and (B) to investigate putative cellular effects 
of the FGFR-4 Arg/Gly polymorphism in melanoma cell lines. 
Methods: The thesis included (I) expression analysis in a panel of melanoma cell 
lines of all four FGFRs including different isoforms, and all 22 FGFs, by standard PCR 
and qRT-PCR, (II) analysis of cellular effects of blockade of FGFR signals by 
dominant-negative receptor constructs, (III) the effect of FGFR blockade on tumour 
growth in vivo by xenotransplantation experiments in SCID mice, (IV) the effect of 
small molecule FGFR inhibitors, versus FGF-2 stimulation on downstream signalling, 
(V) effects of FGF-2 on cell migration and proliferation, (V) investigation of 41 
melanoma samples for FGFR-4 Arg/Gly expression and comparison with clinical 
stage, (VI) effects of the FGFR-4 Arg388 allele on cell migration and proliferation.  
Results: Expression analysis revealed, that FGFR-1 and FGFR-4 are highly 
expressed in nearly all melanoma cell lines, compared to FGFR-2 and FGFR-3. 
Taking non-transformed melanocytes as reference, the expression of FGFR-4 and 
FGFR-2 seems to be highly up-regulated in nearly all melanoma cell lines, while 
expression of FGFR-1 is maintained on a high level and FGFR-3 stays low. In general, 
expression levels of all FGFRs and isoforms were heterogeneous. Truncated FGFR 
isoforms, especially those lacking the TM-domain, were not detected in around half of 
the melanoma cell lines. Considering expression of FGF ligands, FGF-2 was found to 
be highly up-regulated in all melanoma cell lines investigated while FGF-5 was up-
regulated in the vast majority (90%). Expression of FGF18 was found up-regulated in 
40% and FGF-17 and FGF-8 stayed low in all cell lines. Similar to FGF-Receptors, 
ligands were also expressed in a heterogeneous manner. 
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Inhibition of FGFRs by expression of dominant-negative FGFR constructs revealed, 
that blockade of the FGFR-1 pathway seems to be an effective therapeutic approach 
in melanoma cells. In vitro inhibition was tested by proliferation assays, clonogenic 
assays, and soft agar assays. Results have been confirmed in vivo, by 
xenotransplantation experiments in SCID mice. It has been shown, by blocking the 
FGFR-1 pathway, that melanoma cell lines induce apoptosis. This was monitored by 
fluorescence microscopy and propidium-iodide staining, and finally verified by 
immune-blotting determining protein levels of cleaved PARP1 and Caspase 3.  
Cell proliferation was increased around 20-40% when cells were stimulated with 
exogenous FGF-2. Intensity of stimulatory effects depended on endogenous FGF-2 
expression levels. Thus, cell lines with low FGF-2 expression levels were more easily 
stimulated. Migration of melanoma cells was also stimulated about 20-50%, either by 
exogenous FGF-2 or FGF-5. Migration of cells having low endogenous FGF-2 or FGF-
5 expression was more easily stimulated.  
The MAPK- and Akt- signalling pathways were shown to be stimulated by FGF-2. Prior 
incubation with FGFR small molecule inhibitors, PD166866 and SU5402, prevented 
stimulation by FGF-2. However, inhibition of constitutive activation of downstream 
signals by small-molecule FGFR inhibitors alone, could not be shown in this study. 
Homozygous expression of the FGFR-4 Gly388 allele was found to be reduced with 
increasing cancer stage (primary tumours: 62%; metastases: 43%; malignant 
effusions: 20%), in melanoma cell lines. Therefore, the FGFR-4 Arg388 allele is 
suggested to be involved in cancer progression of melanoma. Investigating cell 
migration and proliferation, using stably expressing FGFR-4 Arg388 versus Gly388 
cell lines, revealed no differences considering cell proliferation, but migration was 
increased 2.5 x in one of two FGFR Arg388 cell lines.  
Conclusion: In Vivo as well as in vitro, cell proliferation or tumour growth is reduced 
to about 50%, when infected with adenoviruses bearing dnFGFR1 constructs, 
compared to GFP as control. Our investigation suggests that FGFR-1 inhibition might 
be a promising strategy for melanoma therapy. The FGFR-4 Arg388 allele might 
contribute to melanoma progression. 
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1 Aims of the Study 
 
Recently, so called “targeted therapies” have become an alternative to classical 
chemotherapies for the treatment of advanced tumours in cancer patients. The aim is 
to develop drugs targeting molecules specific for tumour cells. Therefore, targeted 
drugs have the potential for enhanced anti-cancer impact, and simultaneously avoid 
problems of severe adverse effects based on interactions with normal tissue. Thus, 
ideal targets need to have two important characteristics, they have to be specific for 
malignant cells and have to be “drug-able”, meaning that they are able to interact with 
and respond to the drug application.  
Fibroblast Growth Factors (FGF1-23) and Fibroblast Growth Factor Receptors 
(FGFR1-4) are critically involved in tumour cell growth, survival and angiogenesis of 
several tumour types. In melanoma several reports have established an oncogenic 
role of acidic FGF (FGF-1), basic FGF (FGF-2) and FGFR-1. Besides, a correlation 
between FGFR-4 protein expression and survival of melanoma patients has been 
described. The recently identified Arg/Gly polymorphism of FGFR-4 is suggested to 
influence cancer progression and cell migration of various tumour types. 
 
The purpose of the study was (A) to evaluate the potential of FGFRs as molecular 
therapy targets for melanoma, and included: Expression analysis in a panel of 
melanoma cell lines of all four FGFRs including different isoforms, and all 22 FGFs, by 
standard PCR and qRT-PCR; Analysis of cellular effects of blockade of FGFR signals 
by dominant-negative receptor constructs; Investigation of effects of FGFR blockade 
on tumour growth in vivo by xenotransplantation experiments in SCID mice; Analysis 
of effects of FGFR inhibitors (Small Molecule Inhibitors) versus FGF-2 stimulation on 
downstream signalling; Investigation of effects of FGF-2 on cell migration and 
proliferation. 
 
And (B) to investigate putative cellular effects of the FGFR-4 Arg/Gly388 
polymorphism in melanoma cell lines, involving: Investigation of 41 tumour samples 
for FGFR-4 Arg/Gly388 expression and comparison with the clinical stage of disease; 
Analysis of effects of the FGFR-4 Arg388 allele on cell migration and proliferation.  
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2 Introduction 
 
 
2.1 Cellular and Molecular Biology of Melanoma 
2.1.1 Melanocytes and Melanin 
 
Melanocytes can be found in a variety of places in the human body. They are present 
in the middle layer of the eye called the uvea, in the inner ear, meninges, bones, 
heart and in the skin. Considering the skin, melanocytes are located in the bottom 
layer, called stratum basale, of the skin´s epidermis and primarily impart skin colour 
(Barden & Koulish, 1983; Markert & Silvers, 1956; Mintz, 1971; Nichols, 1969; 
Theriault & Hurley, 1970).  
 
In the human skin, melanocytes are distributed as single cells within the basal layer 
of the epidermis (Figure 2.1) and are embedded in a tissue environment consisting of 
multiple cell types, such as keratinocytes, fibroblasts, immune-regulatory cells and 
endothelial cells. They are present in a life-long stable ratio of 1:5 with basal 
keratinocytes and this balance is maintained by highly regulated induction of 
melanocyte division. As long as melanocytes are bound to the basement membrane 
they are not able to proliferate. They need to decouple from the basal lamina as well 
as from bound keratinocytes, retract their dendrites, divide and migrate along the 
basement membrane until they re-couple to the membrane and to keratinocytes. 
Melanocyte growth is controlled by surrounding keratinocytes, they divide quite 
slowly, compared to other cells of the human body (Haass & Herlyn, 2005; Haass, 
Smalley et al., 2005).  
 
However, it is suggested that cell division can be accelerated significantly by various 
environmental factors, most importantly by ultraviolet (UV) light, which stimulates not 
only cell division but also the production of cytoprotective pigments, known as 
melanin (Herlyn, Ferrone et al., 2001; Satyamoorthy, Muyrers et al., 2001). 
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Figure 2.1: Location and distribution of melanocytes and melanin in the 
human skin (http://training.seer.cancer.gov/ss_module14_melanoma/unit02_ 
sec02_anatomy.html; 26.07.2009).  
 
 
Various studies of animal models suggest, that genetic as well as environmental 
cues might play a role in adult pigment patterning and thus prevalence of 
melanocytes and production of melanin (Meredith & Sarna, 2006). Melanin mainly 
functions as potent free radical scavenger in humans, protecting the DNA of skin 
cells from reactive oxygen species (ROS) that can be formed in high concentrations 
by UV light (Herrling, Jung et al., 2008; Jung, Seifert et al., 2008).  
 
In the normal skin, a homeostatic balance between melanocytes and surrounding 
cells can be found. This fine-tuned balance is held upright by direct or indirect cell to 
cell interactions, activating or suppressing a great variety of signalling pathways, as 
well as by the extracellular matrix (ECM). For instance, melanocytes are under 
control of keratinocytes regulating their proliferation (Herlyn, Ferrone et al., 2001), 
while the basement membrane (basal lamina), which is a specialized, dense form of 
ECM, prevents melanocytes from migrating into the dermis. It is also known, that 
mature “non-transformed” melanocytes are not able to survive in the dermis, due to 
the completely different environment (Herlyn, Ferrone et al., 2001; Jung, Seifert et 
al., 2008). 
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2.1.2 Melanomagenesis 
 
 
In general, melanoma develops as a consequence of multifactorial perturbations 
(Figure 2.2) and its ability to invade and metastasize to distant organs suggests its 
adaptability to varying microenvironments. It can be considered as a disease of 
homeostatic imbalance in the skin, and its development can be influenced by a great 
variety of skin components (Satyamoorthy & Herlyn, 2002).  
 
 
 
Figure 2.2: Factors suggested to influence melanoma development. A change 
of epistasis is thought to be the entry point of melanoma development and  is 
achieved by environmental, genetic as well as by epigenetic alterations in the 
skin tissue. The homeostatic imbalance in the tissue can become more dynamic 
and irreversible, leading to melanoma progression (Satyamoorthy & Herlyn, 
2002). 
 
 
 
 
2.1.3 Homeostatic Imbalance and Dysplastic Nevi 
 
The process of homeostasis determines whether cells remain quiescent, 
differentiate, proliferate or undergo apoptosis, in the normal environment. 
Considering melanocytes in the skin, homeostasis is mainly controlled by 
keratinocytes, controlling their growth and behaviour by cell-cell adhesion molecules 
as well as by paracrine growth factors.  
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Three major mechanisms are proposed to be involved in the process of escaping the 
control of keratinocytes, namely (a) down-regulation of receptors involved in 
communication with keratinocytes, (b) up-regulation of signalling molecules and 
receptors important for communication between melanoma-melanoma and 
melanoma-fibroblast cells, and (c) loss of anchorage to the basement membrane 
(Haass, Smalley et al., 2005). 
 
During the first stage of melanoma development, melanocytes fail to distribute 
normally and remain in clusters instead, forming a dermal or dysplastic nevus. They 
may be able to break the basal lamina, the basement membrane barrier, however 
cells are prevented from aggressive cell division due to lack of transformation 
(Satyamoorthy & Herlyn, 2002). Melanocytes acquire the ability to express specific 
cell surface molecules allowing them to adhere, survive, grow and migrate. Examples 
of up-regulated receptors and signalling molecules are: N-cadherin, Mel-CAM and 
zonula occludens protein-1 (ZO-1) (Haass, Smalley et al., 2005). On the other hand, 
the cells stop expressing genes restricting migration, such as E-cadherin, which is 
known for suppressing invasion and is expressed by melanocytes and keratinocytes 
in the normal skin environment (Danen, Sonneveld et al., 2000; Gruss & Herlyn, 
2001). Besides E-cadherin, also P-cadherin, desmoglein and connexins were found 
to be frequently down-regulated. Cell-matrix interactions are known to shift from 
lamin and collagen IV mediated adhesion to collagen I and vitronectin-binding 
receptors during early melanoma development (Gruss & Herlyn, 2001; Haass, 
Smalley et al., 2005). E-cadherin facilitates homophilic interaction and restricts cell 
division of melanocytes without killing them. In contrast, fibroblasts and endothelial 
cells express N-cadherin (Hsu, Andl et al., 2000; Hsu, Meier et al., 2000; Hsu, 
Wheelock et al., 1996). Cadherins are highly glycosylated cell surface proteins and 
are known to be an integral part of cell-cell adherens junctions, promoting calcium-
dependent homotypic and heterotypic cell-adhesion as well as intercellular 
communication. E-, N- and P-cadherins, also considered as the classical cadherins, 
are known to be expressed during different stages of melanoma progression 
(Steinberg & McNutt, 1999; Vleminckx & Kemler, 1999).  
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The progressive loss of E-cadherin during melanoma development consequently 
leads to the disruption of adherens junctions and may impart the loss of terminal 
differentiation to melanocytes (Herlyn, Padarathsingh et al., 2002; Satyamoorthy & 
Herlyn, 2002). These complex formations convey cell to cell interactions and 
adhesion by indirect linkage of their cytoskeleton. Besides cadherins and several 
adaptor proteins, also catenins are part of these complexes and are known to be 
potent regulators of gene expression (Figure 2.3).  
 
Transformed melanocytes lose the ability to express E-cadherin, but start to express 
N-cadherins instead. This cadherin subtype switching promotes interactions with 
endothelial cells as well as fibroblasts, subsequently leading to tumour-host cell 
interactions, migration and tumour cell invasion (Furukawa, Fujii et al., 1997). It was 
shown, that over-expression of E-cadherin in melanoma cells prevents their growth, 
invasion into the dermis and leads to cell apoptosis (Hsu, Andl et al., 2000; Hsu, 
Meier et al., 2000). However, it is still not known which molecular changes lead to the 
E- to N-cadherin switch. Mutations within the E-cadherin gene or epigenetic 
mechanisms, such as DNA methylation, are apparently not involved in human 
melanomas. There is evidence, that transcriptional silencing of the E-cadherin gene 
by transcription factors may be involved (Comijn, Berx et al., 2001). 
 
N-cadherin is suggested to be the major inductor for the formation of a dysplastic 
nevus. It mediates the homotypic aggregation of melanoma cells and heterotypic 
interactions to vascular endothelial cells and fibroblasts (Utton, Eickholt et al., 2001) 
and is thought to facilitate cell migration into the dermis as well as the process of 
intra-vascularization (Satyamoorthy & Herlyn, 2002). It is also known, that N-cadherin 
is able to interact physically with the fibroblast growth factor receptor-1 (FGFR-1), 
which promotes growth and the formation of neurites (Utton, Eickholt et al., 2001). 
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Figure 2.3: Cell-cell adhesion between normal melanocytes and melanoma cells. (A) In 
the normal skin melanocytes are surrounded by keratinocytes. E-cadherins and 
desmoglein adhere both cell types to each other and enable them to communicate via 
gap junctions. (B) In contrast, melanoma cells are present as clusters, they migrate into 
the dermis and are able to interact with three different cell types. They interact with each 
other through N-cadherins, Mel-CAM/ ligand, αvβ3 integrin/L1-CAM, ALCAM and 
connexins, with fibroblasts through N-cadherin and connexins, and with endothelial cells 
through N-cadherin, Mel-CAM/ligand, αvβ3 integrin /L1-CAM, α4β1 integrin/VCAM-1 and 
connexins (Haass & Herlyn, 2005; Haass, Smalley et al., 2005). 
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2.1.4  Genetic Abberations and Melanoma Progression 
 
Melanoma begins as a benign nevus, which consists of a clonal population of 
hyperplastic melanocytes locked in a state of cellular senescence and not displaying 
aggressive proliferation due to lack of transformation. It is suggested that cell 
senescence represents a true barrier to the progression of melanoma and once it is 
overcome, the nevus can progress to more lethal stages with increasing proliferation 
ability. Therefore, the investigation of the mechanism(s) by which melanoma evades 
senescence has been studied. In most cells senescence is regulated by 
combinational activities within Rb and p53 pathways. However, it seems that 
melanocyte senescence is regulated in a distinct manner (Ha, Merlino et al., 2008; 
Satyamoorthy & Herlyn, 2002), (Figure 2.4). 
 
 
Figure 2.4: Oncogenes and Tumour-Suppressor Genes suggested to be involved in 
melanoma progression. Tumour progression is  initiated by expression or down-regulation 
of molecules, which are affected by environmental, genetic and epigenetic events. The 
model also shows experimental stages of melanoma progression.  A dysplastic nevus, 
also called multiple atypical nevus, develops more likely into melanoma than a 
melanocytic nevus. Melanomas in the stage of Radial Growth Phase (RGP) were shown 
to be less aggressive and non-tumourigenic in SCID mice. However, in the Vertical 
Growth Phase (VGP) and in the metastatic stage, melanomas are becoming more and 
more aggressive and tumourigenic due to several biological and molecular changes, 
some of these are indicated (Satyamoorthy & Herlyn, 2002). However, the recently 
identified BRAF oncogene is not shown in this figure. It has been shown, that around 
60% of melanomas contain activating kinase mutations, concerning this member of the 
MAPK-pathway (Montagut, Sharma et al., 2008; Smalley, Nathanson et al., 2009). 
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Due to continuous and high exposure of melanocytes to environmental hazards, such 
as sunlight and chemicals, one might suggest, that melanomas solely demonstrate 
UV signature mutations. However, this is not the case. Compared to other tumours, 
mutations in the tumour suppressor gene p53 are found in less than 5% of 
melanomas, thus are very rare (Herlyn, Ferrone et al., 2001). In cases exposed to 
sunlight, mutations in the RAS oncogene contributed less than 21% (Herlyn & 
Satyamoorthy, 1996). Considering mutations in the tumour suppressor p16INK4A, they 
were found in less than 25% of melanomas (Herlyn, Ferrone et al., 2001). 
 
Mutations in genes like CDK4, PTEN or ß-catenin were not found to be import in 
melanomas. Germ line mutations or deletions in chromosome 9p21 were found in 
about 20-30% of all cases, while genetic predisposition of familial melanoma did not 
exceed more than 10% (Satyamoorthy & Herlyn, 2002). The chromosome segment 
9p21 harbours a variety of cell cycle inhibitors and tumour suppressors, such as 
p16INK4A and p15INK4B. Through the use of shared coding regions and an alternative 
reading frame the CDKN2A gene codes for two proteins, the cell cycle inhibitor 
p16INK4A and p14/ARF (Becker, Rizos et al., 2001). The p14/ARF protein is known to 
stabilize p53 by interfering with MDM2, forming a p53/MDM2 protein complex (Rocco 
& Sidransky, 2001). However, the majority of mutations in this region affect the 
p16INK4A locus, while 40% happen in both p16INK4A and p14/ARF (Rizos, Darmanian 
et al., 2001; Rizos, Puig et al., 2001), (Figure 2.5).  
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Figure 2.5: Suggested Arf regulation of melanocyte senescence, 
independent from p53. The Arf/p53 and Ink4a/Rb pathways are proposed 
to be both implicated in senescence. It was shown, that in mouse 
melanocytes Arf can promote p53 independent degradation of E2F1. 
These mechanisms, together with others (question mark), might trigger 
senescence in melanocytes (Ha, Merlino et al., 2008). 
 
 
 
Two important questions are left open, (1) by which mechanism(s) melanoma cells 
evade senescence, if p53 is not involved and (2) why melanoma remains chemo-
radiation resistant. It seems, that p53, despite its wild-type status, is not able to 
modulate melanoma cells, which is the case in nearly all other tumour cells. In 
melanoma cells, p53 accumulates in the nucleus, but its transcriptional activity is 
weak (Satyamoorthy, Chehab et al., 2000).  
 
This indicates, that p53 is kept in an inactive state by other inhibitory factors or post-
transcriptional mechanisms. It has been shown, that in melanoma cells, like in 
sarcomas, the MDM2 protein is over-expressed (Freedman & Levine, 1999; 
Freedman, Wu et al., 1999). MDM2 is known to inactivate p53 by regulating its 
degradation (Rocco & Sidransky, 2001). 
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In the case the p16INK4A locus would be inoperative, the p14/ARF derived from the 
same locus might be less functional and MDM2 is able to inhibit p53. What´s more, 
expression of Bcl-2, an anti-apoptotic factor, is known to inhibit not only the p53-
dependent, but also the independent apoptotic mechanisms (Hsu & Hsueh, 2000). A 
further target, that lies downstream of p53, is Apaf-1 (apoptotic protease activating 
factor-1), which is known to initiate the proteolytic cascade by activating caspase 9. It 
has been shown, that Apaf-1 is frequently inactivated in melanoma cells (Soengas, 
Capodieci et al., 2001). In contrast, caspase 9 activation and initiation of apoptosis 
can be inhibited by Akt/PKB signalling (Soengas, Capodieci et al., 2001; Tang, Zhou 
et al., 2000).  
 
Apart from regulating apoptosis, the Akt/PKB pathway is also thought to play an 
important role in cellular metabolism. A variety of growth factors have been found to 
activate the Akt/PKB signalling pathway, such as HGF/SF secreted by melanoma 
cells or IGF-I secreted by the surrounding stroma, known to function in an autocrine 
and paracrine manner (Delehedde, Seve et al., 2000; Satyamoorthy, Li et al., 2001) 
and leading to increased proliferation. It has been suggested, that constitutive 
activation of Stat1 and Stat3 together with members of the MAP kinase pathway 
might play an important role in melanoma cells (Kirkwood, Farkas et al., 1999).  
 
In this context, it has been shown recently, that activating BRAF kinase mutations 
arise in around 7% of all human tumours and in the majority of melanomas 
(Montagut, Sharma et al., 2008; Smalley, Nathanson et al., 2009). The RAF-mitogen-
activated protein / extracellular signal regulated kinase (ERK) kinase-ERK signalling 
cascade has been validated in preclinical studies as potential therapeutic target and 
selective RAF kinase inhibitors are in clinical development (Montagut, Sharma et al., 
2008). 
 
The investigation of the precise role of multiple factors in a multicellular environment 
is difficult and requires a lot of effort and time, but is essential to understand the 
cross-talk between several signal transduction pathways, their redundancies and 
finally the process of melanoma development.  
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2.2 Fibroblast Growth Factors (FGF) and  
FGF-Receptors 
 
2.2.1 Evolution of the FGF and FGFR Gene Family 
 
The FGF signaling pathway is conserved throughout metazoan evolution. Twenty-
two FGFs have been discovered to date in mice and humans, FGF1-FGF23.  FGF-
19 is the human ortholog of mouse FGF-15. In total the family consists of 22 
members (Ornitz & Itoh, 2001). The nomenclature does not imply, that all FGFs have 
a proliferative activity on fibroblasts, instead is based on biological characteristics of 
the first discovered family members as well as on the strong structural homology 
(Powers, McLeskey et al., 2000). If all members of a given group of genes have 
above 50% amino acid identity it is traditionally considered a gene family (Thornton & 
DeSalle, 2000). The human FGF gene family can be divided into seven subfamilies 
(Figure 2.6), members of these subfamilies share increased sequence similarity as 
well as biochemical and developmental properties (Ornitz & Itoh, 2001). Recently it 
has been shown, that FGF homologous factors (FGF11-14), although having high 
sequence identity with the FGF family, do not activate FGF receptors (FGFRs). 
Therefore, are not generally considered members of the FGF family (Beenken & 
Mohammadi, 2009).  
Nearly all FGF genes are scattered throughout the genome, which indicates their 
generation by gene duplications and translocations during evolution (Ornitz & Itoh, 
2001). The family seems to have expanded in two phases, namely during early 
metazoan evolution and during the evolution of early vertebrates. In the first phase 
the FGFs expanded by gene duplication from two or three to six genes, while in the 
second phase the expansion took place by two large gen(om)e duplications (Horton, 
Mahadevan et al., 2003; Sidow, 1996; Thornton & DeSalle, 2000). 
The FGF-Receptor family by contrast consists of only four functional genes (FGFR1-
4), human receptor genes contain 18 exons and have an identical exon-intron 
organization. (Powers, McLeskey et al., 2000). Alternative splicing has increased the 
functional diversity, and thereby also specifity (Table 2.1), significantly during 
evolution. Phylogenetic analysis indicates that mechanisms which regulate 
alternative splicing have been conserved during evolution (Itoh & Ornitz, 2004; 
Mistry, Harrington et al., 2003) 
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Figure 2.6: Members of the human fibroblast growth factor 
(FGF) gene family can be arranged into seven subfamilies that 
indicate evolutionary relationships. Evolutionary distance is 
proportional to the branch lengths. The human FGF-19 gene is 
thought to be the ortholog of the FGF-15 mouse gene (Ornitz & 
Itoh, 2001). 
 
. 
 
 
Table 2.1: FGF-Receptor genes, their chromosomal localizations, splice variants and ligand-
specifities for FGF1-FGF10, are shown (Ornitz & Itoh, 2001).  
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The genes are distributed throughout the genome similar to FGF genes, but without 
apparent relationship between the chromosomal locations. The distribution of the 
genes indicates the probability, that these are similarly derived from a common 
ancestral gene by two waves of gen(om)e duplication during early vertebrate 
evolution. Besides recent findings suggest that the expansions of the FGFR family 
and FGF subfamilies were linked in time. This kind of co-evolution presumably 
facilitated complex vertebrate evolution by increasing combinatorial specifities 
between ligand-receptor pairs (Itoh & Ornitz, 2004).  
 
 
2.2.2 Structural and Functional Properties of FGFs and 
FGFRs 
2.2.2.1 Fibroblast Growth Factors (FGFs) 
 
Fibroblast growth factors are polypeptide growth factors and are able to induce 
chemotactic, mitogenic and angiogenic activity in cells of mesodermal and 
neuroectodermal origin (Basilico & Moscatelli, 1992). Members of the FGF family 
possess a central core of around 140 amino acids which is highly homologous 
between different family members. This core folds into twelve anti-parallel ß-strands 
that form together a cylindrical barrel. The barrel is closed by the more variable 
amino- and carboxy-terminal stretches (Ago, Kitagawa et al., 1991; Zhang, Cousens 
et al., 1991). The historical nomenclature (FGFs) of the first of these proteins was 
based on their biological activity, however is not meant to imply that all of them have 
fibroblast stimulating activities but rather that they belong to the same family because 
of their structural relation (Powers, McLeskey et al., 2000). 
The vast majority of FGFs (FGFs 3-8, 10, 17-19, 21 and 23) are secreted by the 
Endoplasmic Reticulum-Golgi pathway. These FGFs are readily secreted from cells 
and possess N-terminal signal peptides, which are cleaved in the ER according to 
the classical pathway. FGFs 9, 16 and 20 have uncleavable N-terminal hydrophobic 
sequences and maybe are secreted independent of the classical pathway. Others 
(FGFs 1 and 2) totally lack signal peptides and are not secreted, but can be released 
by damaged cells or by an exocytotic mechanism which is independent of the ER-
Golgi pathway (Ornitz & Itoh, 2001), (Table 2.2).   
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FGFs 11-14 also lack signal peptides, but remain intracellular and function within 
cells in a receptor independent manner. FGF-22 remains attached to the cell surface 
and possesses a putative N-terminal signal peptide (Schoorlemmer & Goldfarb, 
2001).  
 
Table 2.2: Characteristics of the FGF family members (Miralles, Czernichow et al., 1999; Ornitz, Xu et al., 
1996; Powers, McLeskey et al., 2000; Xu, Lawshe et al., 1999). 
Name Synonym(s) High-Affinity Receptors Comments 
FGF-1 acidic FGF (aFGF) FGFR1 (IIIb+IIIc) 
FGFR2 (IIIb+IIIc) 
FGFR3 (IIIb+IIIc) 
FGFR4 
no signal sequence; nuclear 
localisation signal (intracrine 
stimulation of DNA synthesis); one 
mRNA form; strong heparin affinity 
FGF-2 basic FGF (bFGF) FGFR1 (IIIb+IIIc) 
FGFR2 (IIIc) 
FGFR3 (IIIc) 
FGFR4 
no signal sequence; four protein 
isoforms (through alternating start 
codons); some possess nuclear 
localization signals; 55% sequence 
identity to FGF-1; phosphorylation 
by PKA/PKC (physiological roll still 
unclear); strong heparin affinity 
FGF-3 int-2 FGFR1 (IIIb) 
FGFR2 (IIIb) 
signal sequence (loss leads to 
accumulation in nucleus and to 
inhibition of proliferation); nuclear 
localization motif; site of mouse 
mammary tumour virus (MMTV) 
integration; 44% homology to FGF-
2; primarily expressed during 
development 
FGF-4 kaposi FGF (kFGF); hst-1 FGFR1 (IIIc) 
FGFR2 (IIIc) 
FGFR3 (IIIc) 
FGFR4 
signal sequence; identified by 
screening of stomach tumours and 
Kaposi`s sarcomas; 42% homology 
to FGF-2 
FGF-5  FGFR1 (IIIb+IIIc) 
FGFR2 (IIIb+IIIc) 
FGFR3 (IIIb+IIIc) 
FGFR4 
signal sequence; identified by 
screening human tumour cell lines 
promoting the growth of 3T3 
fibroblast growth without serum 
growth factors; glycosylation site 
FGF-6 hst-2 FGFR1 (IIIc) 
FGFR2 (IIIc) 
FGFR4 
signal sequence; glycosylation site 
(glycoprotein shows no change in 
biological activity similar to 
glycosylated FGF-5) 
FGF-7 KGF FGFR2 (IIIb) signal sequence; glycosylation site; 
specific for epithelial cells 
FGF-8 AIGF FGFR1 
FGFR2 (IIIc) 
FGFR3 (IIIc) 
FGFR4 
all seven isoforms with signal 
sequences; alternate splicing using 
six exons; frequently activated in 
MMTV infections similar to FGF-3/4 
FGF-9 GAF FGFR2 (IIIc) 
FGFR3 (IIIb+IIIc) 
FGFR4 
no signal sequence - although 
efficiently secreted; probably using 
alternative secretion pathway; not 
angiogenic 
FGF-10 KGF-2 FGFR1 (IIIb) 
FGFR2 (IIIb) 
signal sequence; high sequence 
similarity to FGF-7; both are 
mitogenic for keratinocytes and 
expressed in stromal cells, but FGF-
10 has a much higher affinity to 
heparin which thereby potentiates 
activity 
FGFs 11-14  Unknown? no signal sequences; all contain 
nuclear localization signals; share 
58% to 71% sequence homology 
between themselves, but less than 
30% with other FGFs 
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FGF-15  Unknown? suggested to play a role during 
embryogenesis; gene is activated by 
E2A-Pbx1 
FGFs 16-19  FGF17; FGFR1 (IIIc), FGFR2 
(IIIc) 
all contain signal sequences; 
suggested to play a role during 
development 
FGF-20 XFGF20 Unknown? high sequence similarity to FGF-9; 
expressed in early stages of 
embryonic development 
 
 
 
2.2.2.2 FGF-Receptors (FGFRs) 
 
Different FGFs can be specific for diverse target cells and are able to induce a variety 
of diverse effects, like chemotaxis, angiogenesis or mitogenesis for example. To 
achieve this amount of diversity the signalling system needs a great variety of 
different receptors. In general there exist two mechanisms to achieve this FGFR 
diversity, namely by different expression of FGFR genes and alternative splicing of 
the same gene (Figure 2.7). Three out of four existing FGFR genes, if expressed, 
can give rise to a variety of receptor isoforms by using different splice variants 
(Powers, McLeskey et al., 2000). 
 
 
 
Figure 2.7: Variety of FGF-Receptors by using the mechanism of alternative splicing. Concerning the 
FGFR-2 gene, Ig domain IIIb is pre-dominantly expressed in the epithelial lineage, while Ig IIIc 
domains are only expressed in the mesenchymal lineage (Orr-Urtreger, Bedford et al., 1993; Powers, 
McLeskey et al., 2000; Yan, Fukabori et al., 1993). 
 
 
 
 
27 | P a g e  
 
Comparing the mRNAs of the FGFR genes 1, 2 and 3, one finds a remarkable 
conservation of the exon/intron arrangement (Ornitz, Xu et al., 1996). Variations in 
using different splice sites or the introduction of early stop codons may results in 
secreted receptors that do not possess transmembrane domains (Johnson & 
Williams, 1993). Alternatively, it may lead to the loss of the IgI domain, which alters 
the binding affinity of FGF-1 and FGF-2 to FGFR-1 significantly, or in different IgIII 
domains (Johnson, Lee et al., 1990; Johnson & Williams, 1993), (Figure 2.8 and 2.9).  
 
 
Figure 2.8: Coding exons of the human FGFR-1 gene. The 5` untranslated region is the dashed 
line at the beginning, followed by the signal sequence shown as striped box, IgI domain, the acidic 
sequence as open box, IgII and possible IgIII domains. The arrows indicate alternative splice sites, 
while asterisks are stop codons, thus the usage of Ig IIIa consequently leads to a stop of 
translation. The black box indicates the transmembrane domain, which is followed by a split kinase 
domain, shown as two stippled boxes (Johnson, Lu et al., 1991; Powers, McLeskey et al., 2000).  
 
 
It is suggested that the usage of different IgIII domains (IIIa,IIIb or IIIc) is most 
important for the FGF-FGFR specifity. Coding exons of these three possible domains 
are situated in exactly the same order in FGFR-1, FGFR-2 and FGFR-3. The 
exception is FGFR-4 with only one possible IgIII domain (Chellaiah, McEwen et al., 
1994; Johnson, Lu et al., 1991; Vainikka, Partanen et al., 1992). The usage of the 
IgIIIa splice variant leads to a truncated protein that lacks the TM- and kinase 
domains, thereby is secreted and probably acts to sequester released FGFs thus 
inhibiting their binding to functional receptors (Powers, McLeskey et al., 2000). 
 
 
 
Figure 2.9: Arrangement of exons and introns of the human FGFR-1 gene. Arrows and vertical 
dashed lines indicate the positions of intron sequences, while the numbers above indicate the size of 
the intron in kilobases. Assigned exon numbers are indicated by numbers between vertical dashed 
lines below the coding region (Johnson, Lu et al., 1991). 
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Concerning the FGFR-2 gene, Ig domain IIIb is exclusively expressed in the epithelial 
lineage, while Ig IIIc domains are only expressed in the mesenchymal lineage (Orr-
Urtreger, Bedford et al., 1993; Powers, McLeskey et al., 2000; Yan, Fukabori et al., 
1993). As IgIIIb and IgIIIc domains are more homologous between different FGFR 
genes, one might suggest that specifity of binding is regardless of the expressed 
FGFR gene. This is not the case, FGF-7, for instance binds to FGFR-2 (IIIb) but not 
to the IIIb domain of FGFR-1 or FGFR-3 (Table 2.3). Thus, there have to be other 
FGFR domains that confer binding specifity and differ between FGFR genes (Ornitz, 
Xu et al., 1996; Powers, McLeskey et al., 2000). It has been shown, that the loss of 
IgI alters the binding of FGF-1 and FGF-2 to FGFR-1 significantly (Johnson & 
Williams, 1993). 
 
Table 2.3: Affinities of FGFs 1-9 to FGF-Receptor isoforms, indicating ligand-receptor specificity determined by 
mitogenic stimulation (Ornitz, Xu et al., 1996). 
 
 
 
 
 
 
 
 
 
 
 
2.2.2.3 The FGF-Heparin Interaction and its Role in FGFR Activation 
 
A defining feature of FGFs is their interaction with heparin or glycosamino-glycan 
heparan sulfate. Heparin is a polymer composed of a disaccharide chain of 
alternating iduronic acid and glucosamine moieties and each unit may contain a total 
of three sulfate groups that convey a strong negative charge. The glycosaminoglycan 
heparan sulfate by contrast, also contains glucuronic acid moieties, but otherwise is 
structurally similar to heparin (Faham, Hileman et al., 1996). Specific heparin-binding 
domains in FGFs are required for a strong binding to heparin. It is suggested that 
these binding sites are composed of groups of basic amino acids and are eighter 
already existent in the primary sequence or brought together by the secondary 
structure of the folded polypeptide (Baird, Schubert et al., 1988; Faham, Hileman et 
al., 1996).  
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The binding of Fibroblast Growth Factors to these extracellular polysaccharides may 
have several functional consequences. It was shown that the interaction stabilizes 
FGFs by preventing thermal denaturation and proteolysis and besides creates a local 
reservoir of growth factors which is required for effective activation of FGF-receptors 
(Damon, Lobb et al., 1989; Gospodarowicz & Cheng, 1986; Ornitz & Itoh, 2001). FGF 
binding proteins in general, increase the bioavailability of FGFs and might facilitate 
the receptor activation (Tassi, Al-Attar et al., 2001). The formation of a local reservoir 
implies that the signalling pathway could be spatially regulated and besides a large 
supply of FGFs may be mobilised from it. 
 
The mobilization from the ECM may itself be highly regulated thereby allowing an 
indirect control of signalling. For the presentation of the FGFs to a particular 
population of cells, the growth factors have to be localized in order to be useful in 
organised development and prevention of diffusion (Cohn, Izpisua-Belmonte et al., 
1995). This kind of regulation may be specifically important in the process of 
angiogenesis, which is known for its complex regulation due to a variety of positive 
and negative factors. For the release of the FGFs from the ECM there are currently 
two proposed mechanisms, namely the enzymatic cleavage of ECM components or 
by the binding to a carrier protein (FGF-BP), which then can deliver bound growth 
factors to their receptors. 
 
Concerning the FGF-Receptor activation, the current understanding is that FGFs 
induce receptor dimerization thereby activating their receptors, and that this 
dimerization is highly facilitated by glycosaminoglycan heparan sulfates and heparin 
(Powers, McLeskey et al., 2000). This facilitation may occur by the recruitment of 
FGFs to the cell surface thereby increasing their concentration and by inducing a 
conformational shift in either FGFs or FGF-Receptors (Baird & Klagsbrun, 1991; 
Klagsbrun & Baird, 1991). Recently very similar models have been established to 
explain the HLGAG (Heparin-like Glycosaminoglycan) -FGF-FGFR complex.  
 
In these independently proposed models a (2xFGF:2xFGFR) tetramer is stabilized by 
HLGAG (heparin-like glycosaminoglycan) binding across this tetramer (Figure 2.10). 
The IgII and IgIII domains wrap around one FGF molecule in each of the FGF-FGFR 
pairs.  
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Together with the other pair, a highly positive canyon at the IgII-FGF interface is 
formed, in which a single HLGAG can bind. The models differ in a few possible 
interactions, all three however, have in common the interactions between HLGAGs 
and both FGFs and FGFRs, as well as the numerous interactions between FGFs and 
their receptors (Davis, Venkataraman et al., 1999; Plotnikov, Schlessinger et al., 
1999; Stauber, DiGabriele et al., 2000; Venkataraman, Raman et al., 1999; 
Venkataraman, Shriver et al., 1999).   
 
 
Figure 2.10: Shows the proposed model for the HLGAG-FGF-
FGFR complex (Powers, McLeskey et al., 2000).  
 
 
 
2.2.2.4 FGF-Receptor Activation, Auto-Inhibition and Signal 
Transduction 
 
After the ligands are bound and have induced dimerization, the receptors are capable 
of phosphorylating specific tyrosine residues on their cytoplasmic tails. The 
phosphorylation can take place either on their own cytoplasmic tail or on the 
neighbouring one, which can be seen as auto- and transphosphorylation respectively 
(Lemmon & Schlessinger, 1994; Schlessinger & Bar-Sagi, 1994).  
 
FGF-Receptor dimerization and subsequent transphosphorylation is not restricted to 
homodimers but can take place also between heterodimers (Bellot, Crumley et al., 
1991). This increases complexity of the FGF signalling significantly and opens further 
opportunities for signal regulation. 
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Figure 2.11: Schematic diagram of the FGFR. Regions involved in the mechanism of auto-inhibition 
as well as ligand binding are indicated. IgI-IgIII are shown as D1-D3 (Mohammadi, Olsen et al., 2005). 
 
FGF signalling components are mainly co-localized which implicates the existence of 
a tight auto-inhibitory control. It is suggested, that this mechanism is conveyed by 
the IgI domain as well as by the IgI/IgII linker region containing the acidic box (AB), a 
stretch of acidic amino acids (Figure 2.11). In this proposed model, the flexible 
nature of the IgI/IgII linker region allows electrostatic interaction between the AB 
region and the highly basic heparin binding site (HBS) of IgII, thereby occluding 
heparin binding (Figure 2.12). This interaction results in a disposition of IgI, which 
then starts interacting with the IgII and IgIII region, leading to occlusion of the FGF 
binding interface. It has been shown, that the progression of pancreatic cancers 
towards a more malignant state correlates with an alternative splicing switch of 
FGFR-1, which leads to the expression of isoforms lacking the IgI domain as well as 
the AB region (Mohammadi, Olsen et al., 2005). 
  
 
Figure 2.12: Model for FGFR 
auto- inhibition. IgI-IgIII are shown 
as D1-D3 (Mohammadi, Olsen et 
al., 2005). 
 
 
Once tyrosine residues are phosphorylated, the signal is passed on by the 
recruitment of proteins that recognize and bind to phosphotyrosine residues through 
their Src-homology 2 (SH2) domains.  
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These proteins can either function as adaptors, thus recruiting further target proteins 
by their own specific binding sites, or they become phosphorylated themselves by the 
receptor kinase. In general the propagation of the signal is achieved by induction of a 
conformational change in target proteins which results in the activation of a variety of 
catalytic sites within these proteins (Pawson, 1995a; Pawson, 1995b). 
 
 
 
Figure 2.13: Suggested transduction pathways by the cytoplasmic tails of activated FGF-
Receptors (Dailey, Ambrosetti et al., 2005).  
 
 
Activated tyrosine-kinase substrates, often kinases themselves, can then pass on the 
signal to further targets (Figure 2.13). There are quite a lot of different downstream 
targets and adaptors of many possible transduction pathways which are frequently 
linked to each other thereby leading to various cell responses (Pawson, 1995a; 
Pawson, 1995b; Powers, McLeskey et al., 2000). It is suggested that different FGFRs 
activate quite similar signalling pathways (Table 2.4 and Figure 2.14), because of the 
high degree of homology at the amino acid level (Johnson & Williams, 1993).  
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Table 2.4: Possible FGFR-mediated pathways. 
PLCγ 
signaling 
pathway 
Phospho-lipase Cγ (PLCγ) gets activated by binding to Tyr766 of FGFR-1 with its 
SH2-domain (Mohammadi et al 1992). Then cleaves Phosphatidyl Inositol-4,5-
Bisphosphate (PIP2) to Inositol-Triphosphate (IP3) and Diacylglycerol, that remains 
membrane bound. IP3 is able to diffuse to the endoplasmic reticulum, where it 
facilitates calcium release by binding to specific calcium channels. Both, DAG and 
released calcium, are activating Protein-Kinase C (PKC) (Burgess, Dionne et al., 
1990). 
Src signaling 
pathway 
Src is thought to link FGFR signalling to cortactin, which is a focal adhesion-
associated protein that binds filamentous actin. Src itself is a non-receptor tyrosine 
kinase. This suggested pathway would be an alternative to the PLCγ signalling for 
FGFR mediated alterations of the cytoskeleton (Wu, Ma et al., 1994; Zhan, Plourde 
et al., 1994).  
Crk-mediated 
signaling 
Crk is suggested to link FGF-Receptors to downstream signalling molecules like 
Shc, C3G and Cas. Crk posesses SH2/SH3-domains and functions as adaptor 
protein. Its recruited proteins are thought to propagate a mitogenic signal from 
FGFRs. However, may not have effects concerning cell motility (Larsson, Klint et al., 
1999).  
SNT-1/FRS-2 
signaling 
pathway 
It was also shown, that FGF-Receptors lacking all non-catalytic tyrosine residues 
were able to phosphorylate a novel protein identified as SNT-1 or FRS-2. This 
findings provide an alternative pathway to the phosphotyrosine recruitment of SH2-
containing proteins. Two groups, Whang and Kouhara, independently showed the 
linkage to the Ras/MAPK pathway by SNT-1/FRS-2. Activation of SNT-1/FRS-2 
leads to the recruitment of Grb-2/Sos adaptor protein, which in turn recruits Ras 
(Kouhara, Hadari et al., 1997).  
 
 
 
In the absence of FGFs there must be also a mechanism that prevents FGFR 
dimerization and activation. A proposed model suggests that the binding of divalent 
cations and HLGAGs to an extracellular receptor sequence, a region which promotes 
self-association, may inhibit the dimerization by preventing direct interaction between 
these regions. These extracellular domains, that are thought to promote receptor 
dimerization, are located between IgII and IgIII and range from Glu160 to Lys176 (Kan, 
Wang et al., 1996; Wang, Kan et al., 1997). 
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Figure 2.14: The human FGF-Receptors 2-4 compared to the FGFR-1 at the amino acid level (Johnson 
& Williams, 1993). Note the high degree of homology concerning the kinase domains. 
 
 
 
2.2.2.5 Biological Functions of the FGF Signalling Pathway 
 
It has been shown that FGF signalling plays a significant role in wound healing and 
angiogenesis. The progress of wound repair can be classified into four phases, 
namely inflammation, contraction, repair and regeneration. It is suggested that FGFs 
play a role in at least inflammation, repair and regeneration. The initial inflammatory 
response is characterized by an invasion of blood platelets and other cells from the 
hematopoietic cell lineage that play a role in immune response. This is followed by an 
accumulation of myofibroblasts, which are suggested to differentiate from pericytes 
or mesenchymal stromal cells. The myofibroblasts bind to the injured site and start to 
contract, significantly reducing the area that has to be repaired. Afterwards a 
granulation tissue starts to form, that can be seen as a chief hallmark of the repair 
phase. The granulation tissue is a richly vascularized connective tissue and is 
characterized by excessive migration of fibroblasts and endothelial cells through a 
non-collagenous extracellular matrix that leads to the formation of new capillaries. At 
last collagen will be deposited and newly formed blood vessels will become 
organized. The repair phase is then followed by regeneration, were lost epithelial 
cells are replaced (Powers, McLeskey et al., 2000). 
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It has been shown, that various growth factors, including FGFs, are released due to 
mechanical force from endothelial cells. Thus the release of FGFs and tissue repair 
is in fact stimulated by the wound itself (McNeil, Muthukrishnan et al., 1989). FGFs 
are stored in fibroblasts (Werner, Roth et al., 1991) and endothelial cells (McNeil, 
Muthukrishnan et al., 1989), but also in the extracellular matrix. However, there have 
to be some other signals, except for mechanical stress, for the release of FGFs from 
the stroma and endothelium, because angiogenesis does not exclusively happen due 
to mechanical injury (Powers, McLeskey et al., 2000).  
 
Some FGFs are able to stimulate the proliferation of lymphocytes (Byrd, Ballard et 
al., 1999), may regulate the production of blood platelets and are suggested to play 
an important role in the migration of inflammatory cells (Huber, Zhou et al., 1998; 
Konishi, Ochiya et al., 1996). It is thought to be mainly the powerful proliferative 
effect, that FGFs have on fibroblasts and endothelial cells, which stimulates tissue 
repair (Powers, McLeskey et al., 2000). However, facilitation of cell migration through 
the extracellular matrix by regulating proteolysis and adhesion molecules may also 
facilitate the repair process (Besser, Presta et al., 1995; Coltrini, Gualandris et al., 
1995; Gualandris & Presta, 1995; Presta, Urbinati et al., 1995). Considering the last 
step of wound healing, namely regeneration of the damaged tissue. FGF-7 was 
found to be highly expressed in interstitial cells and the corresponding FGFR-2 (IIIb) 
in the tubular epithelium, after chemically induced renal tubule damage (Ichimura, 
Finch et al., 1996). This suggests, that FGFs are probably facilitating epithelial 
regeneration by a paracrine loop (Powers, McLeskey et al., 2000). 
 
FGFs play a major role in development, particularly in gastrulation, the formation of 
all three germ layers (Hebert, Boyle et al., 1991; Paterno, Gillespie et al., 1989; Sun, 
Meyers et al., 1999) and in organogenesis. Their importance concerning 
organogenesis, was shown especially in that of the lung, limb and the nervous 
system (Crossley, Martinez et al., 1996; Crossley, Minowada et al., 1996; Sekine, 
Ohuchi et al., 1999; Ye, Shimamura et al., 1998). 
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It is known, that FGFs can have diverse effects on different cell types. In some cells, 
activation of FGFRs leads to proliferation, migration or differentiation, while in other 
cell types leads to cell cycle arrest, apoptosis or inhibition of differentiation (Boilly, 
Vercoutter-Edouart et al., 2000). Moreover, the cellular response to FGFs can also 
differ for a specific cell type in a stage-dependent manner. Immature osteoblasts, for 
instance, respond to FGF stimulation by proliferation, while in a later stage of 
development it leads to apoptosis (Mansukhani, Bellosta et al., 2000). The 
phenomenon, in which signals can have different effects, depending on cell type and 
maturational stage, is called “competence”. The molecular reasons for that, are 
thought to be differential presence or activity of FGF signalling components, which 
can be regulated also by other signalling pathways, making the mechanism more 
dynamic as well as more complex (Dailey, Ambrosetti et al., 2005).  
 
 
 
 
 
 
 
 
 
2.2.3 The FGF Signalling Pathway in Cancer 
 
The binding of FGFs to their receptors induces a variety of signal transduction 
pathways, that regulate many different transcription factors involved in cell cycle 
progression and inhibition of apoptosis. This consequently leads to excessive cell 
growth and development of neoplasms. In general, FGFs promote cell growth by at 
least one of three mechanisms, by mitogenesis, promotion of angiogenesis or by 
inhibition of apoptosis (Powers, McLeskey et al., 2000). The FGF signalling system 
also plays an important role in development of metastatic cancer by changing cell 
adhesion, migration and invasiveness (Cavallaro, Niedermeyer et al., 2001; 
Cavallaro, Tenan et al., 2001; Suyama, Shapiro et al., 2002), mainly by interaction 
with adhesion molecules. 
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2.2.3.1 Overexpression of FGFs 
 
In general, there are two possibilities of sources over-expressing FGFs, surrounding 
stromal cells or the tumour cells themselves. At the same time both sources may also 
act as target cells, thus FGFs can function in an autocrine or/and in a paracrine 
manner (Table 2.5). The tumour may secrete FGFs due to mutation, leading to over-
expression, or due to induced over-expression by signals secreted from non-
transformed stromal cells (Takahashi, Fukumoto et al., 1992; Takahashi, Mori et al., 
1990; Takahashi, Hoshimaru et al., 1992). On the other hand, FGFs may be secreted 
by stromal cells, where their expression is activated by signals from tumour cells 
(Samaniego, Markham et al., 1998). Thus surrounding non-transformed stromal cells 
may also change their expression levels, however not due to mutations but as 
response to tumour secreted factors. What´s more, FGFs may also act in an 
intracrine manner. Some do not possess a signal sequence for the classical 
secretion pathway, thereby remain in the cytoplasm or may be secreted by an 
alternative pathway as already mentioned. Others possess a nuclear localisation 
sequence instead, mediating their nuclear translocation. FGFs are probably able to 
directly act on transcription factors or their regulators, without secretion and binding 
to cell surface receptors (Delrieu, 2000; Joy, Moffett et al., 1997; Stachowiak, Maher 
et al., 1997). 
 
Table 2.5: Examples of known cancer related functions of FGF-2 and FGF-5. These two are shown, 
because they are among the best investigated and are highly up-regulated in melanoma, see also 
expression analysis in the Results and Discussion sections. 
FGF-2 Its expression has been shown in over 94% of human gliomas, but has not been detected in 
normal brain (Takahashi, Fukumoto et al., 1992; Takahashi, Mori et al., 1990); when 
released by tumour cells, it may function as autocrine growth factor and paracrine 
angiogenic factor, by binding to FGF receptors on the tumour itself as well as on 
surrounding cells; correlates with the degree of malignancy and vascularity in human 
gliomas (Takahashi, Fukumoto et al., 1992; Takahashi, Hoshimaru et al., 1992); in Kaposi`s 
sarcoma the expression in transformed cells seem to be induced by surrounding non-
transformed stromal cells by release of TNF- α, IL-1 and Interferon-γ (Samaniego, Markham 
et al., 1998); its translocation to the nucleus is suggested to stimulate        S-phase entry 
(Stachowiak, Maher et al., 1997); appears as 18 kDa protein, localising in the cytoplasm 
and shown to be efficiently secreted, as well as high molecular weight (HMW) isoforms, 
mainly accumulating in the nucleus and having different effects on the phenotype (Delrieu, 
2000); 
FGF-5 Has not been detected in fibroblasts of healthy pancreatic tissue, however in cancer-
associated macrophages and fibroblasts (Kornmann, Ishiwata et al., 1997); the expression 
can be activated in fibroblasts due to action of other growth factors, like EGF, PDGF and 
TGF-α, which are indeed present in human pancreatic cancer tissues (Ebert, Yokoyama et 
al., 1995; Korc, Chandrasekar et al., 1992; Werner, Werner-Felmayer et al., 1991; Werner, 
Roth et al., 1991); 
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2.2.3.2 Increased Availability of FGFs 
 
Apart from FGF over-expression by tumour cells or surrounding non-transformed 
cells, it may also be an increased mobilization of FGFs from the ECM (Figure 2.15), 
that leads to a disregulated signalling pathway in cancer. The release may take place 
by an enzymatic cleavage of ECM components, by heparanases or proteases, or by 
binding to carrier proteins, which are then able to deliver freed factors to their 
receptors (Rak & Kerbel, 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15: Possible mechanisms for FGF mobilization from the ECM (Powers, McLeskey et al., 
2000).  
 
The expression of the heparanase gene was shown at the mRNA and protein levels 
in samples of human liver, colon and breast carcinomas as well as in metastatic 
human and rat cell lines. Melanoma cells, transfected with heparanase cDNA, were 
able to metastasize to liver and lung (Hulett, Freeman et al., 1999; Vlodavsky, 
Friedmann et al., 1999), compared to untransfected cells. Heparanases seem to play 
an important role in metastasis and angiogenesis due to mobilisation of FGFs from 
the ECM (Powers, McLeskey et al., 2000).  
 
The same effects are thought to be achieved by the action of proteases. It has been 
shown in vitro, that FGF-2 bound to the ECM can be mobilized by plasmin, which is 
secreted by bovine capillary endothelial (BCE) cells. In turn, FGF-2 is able to 
increase the plasminogen-activator activity in cultured BCE cells providing a positive 
feedback loop (Saksela & Rifkin, 1990). In contrast to enzymatic degradation of the 
ECM, bound FGFs may be also mobilzed by FGF-binding proteins (FGF-BPs). 
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The 17kDa FGF-BP was originally isolated from a human epidermoid carcinoma cell 
line, and was shown to bind covalently and reversibly to FGF-1 and FGF-2 (Wu, Kan 
et al., 1991). Over-expression of FGF-BP in human adrenal adenocarcinoma cell 
lines resulted in a malignant phenotype (Czubayko, Smith et al., 1994).  
 
The binding protein is known for its tight regulation during development, it is 
downregulated in adult tissues and was shown to be frequently up-regulated in early 
stages of carcinogenesis (Czubayko, Liaudet-Coopman et al., 1997; Kurtz, Wang et 
al., 1997). Concerning cancer development, this observations indicate, that 
regulation of the FGF mobilization from the ECM might be as important as regulation 
of FGF production. 
 
 
2.2.3.3 Alterations of FGF-Receptors 
 
Deregulation of the FGF signalling pathway may also result from alteration of FGFRs. 
This receptor alterations can happen in different ways, namely due to point 
mutations, change in expression, alternative splicing and genomic alterations. 
However, not all alterations could be shown to be associated with cancer 
development.  
Activating point mutations in FGFRs have been found in various developmental 
defects (Chun, Siegel-Bartelt et al., 1998; Gripp, Stolle et al., 1998; Li, Mangasarian 
et al., 1997; Mangasarian, Li et al., 1997; Webster, D'Avis et al., 1996; Webster & 
Donoghue, 1996) and have been implicated in the development of human cancers. 
These point mutations result in a ligand-independent activation, and are thought to 
occur in the intracellular kinase domains as well as in extracellular and 
transmembrane domains of FGFRs (Neilson & Friesel, 1996). Alternative splicing has 
been shown to occur with FGFR-3, leading to a receptor protein lacking its 
transmembrane domain, but retaining an intact kinase domain and accumulating in 
the nucleus (Johnson & Allen, 1995). However, the role in human cancers is 
unknown, a novel autocrine pathway in the nucleus has been suggested (Powers, 
McLeskey et al., 2000). Beside point mutations, also gene rearrangements have 
been shown to lead to ligand-independent activation of FGFRs. Gene fusion of 
FGFR-2 with a novel gene, called FGFR activating gene 1 (FRAG-1), leads to a 
constitutively active form of FGFR-2, found in a rat osteosarcoma cell line.  
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The fusion protein is thought to form constitutive dimers, which results in auto-
phosphorylation of FGFR-2 kinase domains (Lorenzi, Horii et al., 1996). In human 
myeloid cells, a chromosomal translocation has been shown to lead to increased 
expression of FGFR-3 resulting in the activation of an FGF-4 dependent autocrine 
loop (Otsuki, Yamada et al., 1999).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 Materials and Methods 
 
3.1 Cell lines and Media 
 
The cell culture unit of the Institute of Cancer Research supplied all melanoma cell 
lines. Roswell Park Memorial Institute (RPMI) medium with 10% fetal bovine serum 
(FBS) was used for all cell lines. RPMI medium was purchased from Sigma Aldrich 
and uses, like most other media, a hydrogen-carbonate buffer system in a solution of 
glucose, salts, amino acids and vitamins. For indicating the pH-value phenol-red was 
added. FBS is used to supply cells with a variety of growth factors, hormones and 
trace elements to make cell survival in culture possible (Sigma Aldrich). 
Penicillin/streptomycin solution was added to the medium only during selection of 
stable transfectants, was bought from PAA and used at an end-concentration of 1%.  
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Table 3.1: Used cell lines, including VM (Vienna Melanoma) numbers, origina and 
histologyb.  
aEstablishment of cell lines from primary tumours (PT), lymph node (LN), subcutaneous 
(SC), bone (BN), brain (BR) metastases, malignant effusions (ME) of malignant melanoma 
and primary melanocytes (PT), from which cDNA was used as control and was obtained 
from primary culture only. bHistology of the primary tumour: ALM, acral lentiginous 
melanoma; NM, nodular melanoma; SSM, superficial spreading melanoma. 
 
 
 
3.2 Standard Growth Conditions 
 
All melanoma cell lines were grown in a humidified incubator (Forma Scientific) at 
37°C and 5% CO2. Tissue culture flasks (T25 (=25cm2), T75 (=75cm2) and T175 
(=175cm 2)) were bought from Greiner Bio-One as well as from BD Falcon. 6-/12- and 
24-well plates were bought from IWAKI, while 15cm tissue culture dishes were 
bought from Sarstedt and 96 well-plates from TPP. The medium used for cell culture 
always contained 10% FBS, except where indicated otherwise. Generated cell lines 
stably expressing the TetR protein, used for generation of inducible expression by 
the Tet-Off Advanced System (Clontech), were always held under doxocyclin (100 
ng/ml), thereby preventing expression of cell toxic genes of interest (See Selection of 
Stable Transfectants). 
Cell Line Origin Histology Cell Line Origin Histology
Mela PM VM-37 Xfoa SC NM
VM-10 Jmum PT SSM VM-18 Pnjc SC ALM
VM-19 Rall PT SSM VM-34 Xbne SC Unknown
VM-30 Wcre PT SSM VM-35 Xdbc SC Unknown
VM-36 Xewl PT SSM VM-9 Gyk BN SSM
VM-44 Xapg PT SSM VM-22 Rima BN NM
VM-2 Gcrf PT NM VM-46 Huma BR NM
VM-7 Gtbs PT NM VM-47 Host BR NM
VM-21 Rhtp PT NM VM-48 Kaka BR NM
VM-23 Rktj PT NM VM-50 Hoin BR NM
VM-25 Tpck PT NM VM-28 Tmfi BR Unknown
VM-32 Wpza PT NM VM-41 Ydfr BR Unknown
VM-33 Wubi PT NM VM-31 Wltj ME NM
VM-38 Xiba PT NM VM-11 Jtst ME NM
VM-5 Grbd LN SSM VM-13 Krfm ME NM
VM-1 Ftsl/a LN SSM VM-16 Myah ME Unknown
VM-20 Rgoh LN NM VM-3 Gesp ME Unknown
VM-4 Glj LN NM
VM-6 Gsta LN NM
VM-8 Gubs/a LN NM
VM-12 Jwmw LN NM
VM-14 Lcwc LN NM
VM-15 Mjzj LN Unknown
VM-17 Nra LN Unknown
VM-24 Shtj LN Unknown
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3.3 Splitting 
 
All melanoma cells in culture grew adherent, thus the medium was aspirated and 
cells were washed once with PBS (2.7 mM EDTA (Merck), 137 mM NaCl (Merck) and 
10 mM Na2HPO4 (Merck); pH 7.4). Trypsin/EDTA (T/E; 0.01% EDTA (Fluka), 0.1% 
Trypsin (Difco)) was added onto the cell layer and incubated at 37°C for about 5 
minutes, the progress of detachement was monitored using the microscope. Cells 
were resuspended in medium and the desired number of cells was transferred into a 
new dish or bottle, containing fresh medium.  
 
3.4 Cell Counting 
 
Cells were counted by using either a Casy Cell Counter (Schärfe) or a Neubauer 
Chamber (Phelan, 2007; Paul Marienfeld GmbH). 
 
 
3.5 Freezing  
 
Cells were grown in 15 cm tissue culture dishes. When dishes were nearly confluent, 
cells were trypsinized and resuspended in 4 ml medium plus 10% FBS. If cells were 
on selection for stable transfectants, the medium also contained the corresponding 
selection reagent as well as penicillin and streptomycin. 1ml of cell suspension was 
transferred into cryotubes (Greiner) and DMSO (dimethylsulfoxid) was added to a 
final concentration of 50 µg/ml. The suspension was immediately put on ice and 
cooled down in a styrofoam container at –80°C for at least 24 hours, but not longer 
than 72 hours. Afterwards, cells were transferred into a liquid nitrogen tank for long 
term storage. 
 
 
3.6 Isolation of RNA   
 
Medium was discarded, and cells were washed with PBS once. Subsequent steps 
were done on ice. Trifast (Peqlab) or Trizol (Invitrogen) was added onto the cell layer 
or cell pellet, if cells were trypsinized and centrifuged before harvest (1.5 ml volume 
was used for 25 cm2 confluent cell layer or for 20 x 106 cell pellet). In case of isolating 
RNA from a cell layer, the cells were scraped into suspension.  
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Cells were transferred into 2 ml Eppendorf tubes. For lysis, cells were vortexed and 
incubated in Trifast solution for about 5 minutes. For RNA extraction, 
chloroform/isoamylalcohol (50:1; 0.2 x vol. Trifast) was added, vortexed and 
incubated again for around 5 min. Cell waste was pelleted at 11.000 g at 4°C for 11 
min. Aqueous supernatant, containing solubilzed RNA, was transferred into new 
Eppendorf tubes and isopropanol (0.5 times vol. Trifast) was added, vortexed and 
again centrifuged at 11.000 g at 4°C for 11 min. Supernatant was discarded and 70% 
EtOH/DEPC (diethylpyrocarbonate-treated ethanol) was added onto the pellet (~500 
µl), vortexed and centrifuged at 7.500 g at 4°C for 7 min. In general, DEPC treatment 
is used for RNase enzyme inactivation by covalent modification of histidine residues. 
The alcohol was removed, the pellet was air dried and taken up in EDTA solution in 
DEPC water (3 mM; 10-30 µl volume). As quality control, purified RNA was loaded 
onto agarose gel (1 µg RNA; 1% agarose gel) and separated. RNA was frozen at –
20°C, or at –80°C for long term storage.  
 
3.7 Determination of RNA concentration 
 
The concentration of purified RNA was determined by OD260 measurement on a 
NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). 
 
 
3.8 Synthesis of cDNA 
 
1 µg RNA was diluted with DEPC water to 11 µl and incubated for denaturation at 
70°C for 10min. It was put on ice and 9 µl cDNA Synthesis Master Mix (MM) was 
added to a total volume of 20 µl. Afterwards, the reaction was incubated for 1.5 hours 
at 37°C. The quality of cDNA was tested by performing standard RT-PCR of a 
“housekeeping gene” followed by agarose gel electrophoresis. cDNA was stored 
frozen at –20°C. 
 
 
 
cDNA Synthesis Master Mix (1 x) Solution (Concentration) Volume (µl)
M-MLV RT buffer (5 x; Promega) 4
Hexanucleotides (20 ng/µl) 1
dNTPs (10 mM) 1
DTT (100 mM) 2
MMLV-RT (200 u/µl; Promega) 1
RNA (1 µg / 11 µl) 11
20 total volume
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3.9 Reverse Transcriptase – Polymerase Chain Reaction      
(RT-PCR) 
 
The RT-PCR Master Mix (MM) was prepared on ice. 1 µl cDNA solution was pipetted 
into 0.2 ml PCR Tube Strips (Bio-Rad), then the MM was added and mixed. 
MyCyclerTM Thermal Cycler (Bio-Rad) was used for RT-PCR. For PCR conditions, 
primer sequences and PCR fragments see tables below, Table 3.2 and Figure 3.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RT-PCR Conditions Gene of Interest Dissociation Annealing Elongation
GAPDH 94 50 72 Temperature (°C)
Time Number of Cycles
3´ 1x
50´´ 50´´ 50´´ 33x
2 1x
FGFRs 94 56 72 Temperature (°C)
Time Number of Cycles
3´ 1x
50´´ 50´´ 50´´ 40x
2 1x
FGFR-4 (Arg/Gly SNP) 95 50 72 Temperature (°C)
Time Number of Cycles
3´ 1x
30´´ 30´´ 30´´ 40x
2 1x
RT-PCR Master Mix (1 x) Solution (Concentration) Volume (µl)
GoTaq colourless buffer (5 x; Promega) 5
dNTPs (10 mM) 0.5
Primer I (20 µM) 0.5
Primer II (20 µM) 0.5
GoTaq polymerase (5 u/µl; Promega) 0.125
Water bidest. 17.375
cDNA 1
25 total volume
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Table 3.2: Primer sequences and expected sizes of FGFR PCR products, including identified receptor 
isoforms and their NM numbers. Alpha splice variants contain IgG-I domains, while beta variants do 
not possess extracellular IgG-I domains. IgG-III domains may differ in sequence in their C-terminal 
part, thus can be sub-classified into IgG-IIIb and -IIIc. Other splice variants are enlisted as associative 
names. 
GENES Primer-Names Exons Amplicon Length (bp) NM Numbers Splice Variants Sequences
FGFR 1 FGFR 1 (A) s 2 CCTCTTCTGGGCTGTGCT
FGFR 1 (A) as 4/5 164 NM_023105 beta CGGGCATACGGTTTGGTT
164 NM_023107 beta
431 NM_023109 alpha
431 NM_023111 alpha
FGFR 1 (B) s 9 IIIc GACAAAGAGATGGAGGTGCT
FGFR 1 (B) as 14 801 NM_015850 IIIc GTTGTAGCAGTATTCCAGCC
801 NM_023105 IIIc
801 NM_023106 IIIc
801 NM_023109 IIIc
801 NM_023111 IIIc
FGFR 1 (B) Ex7 s 7 TCCAGTGGCTAAAGCACATC
FGFR 1 (B) Ex10 as 10 376 NM_000604 IIIb+c ATCTGGCTGTGGAAGTCACTC
376 NM_015850 IIIb+c
376 NM_023105 IIIb+c
376 NM_023106 IIIb+c
376 NM_023109 IIIb+c
376 NM_023111 IIIb+c
FGFR 1 (B) Ex8 IIIb as 8 IIIb ~ 125 ? IIIb CCGCATCCGAGCTATTAATC
FGFR 1 (B) Ex9 IIIc as 9 IIIc 170 NM_000604 IIIc CGCCAAGCACGTATACTC
NM_015850 IIIc
NM_023105 IIIc
NM_023106 IIIc
NM_023109 IIIc
NM_023111 IIIc  
 
 
 
FGFR 2 FGFR 2 Ex2 s 2 GTCACCATGGCAACCTTGTC
FGFR 2 Ex6 as 6 711 NM_000141 alpha CACAACATCCAGGTGGTACG
711 NM_022969 alpha
711 NM_022970 alpha
711 NM_022971 alpha
711 NM_022972 alpha
711 NM_022973 alpha
711 NM_022974 alpha
444 NM_022975 beta
711 NM_022976 alpha
711 NM_023028 alpha
444 NM_023029 beta
366 NM_023030 beta -Acidic box
366 NM_023031 beta -Acidic box
FGFR 2 s 5 AACGGGAAGGAGTTTAAGCAG
FGFR 2 as 9 IIIc 504 NM_000141 IIIc TGGCAGAACTGTCAACCATGC
513 NM_022972 IIIc
504 NM_022973 IIIc
513 NM_023028 IIIc
504 NM_023029 IIIc
FGFR 2 (B) Ex8 IIIb as 8 IIIb 417 NM_022969 IIIb CTCGGTCACATTGAACAGAG
417 NM_022974 IIIb
417 NM_022975 IIIb
417 NM_022976 IIIb
417 NM_023030 IIIb
417 NM_023031 IIIb
FGFR 2 (B) Ex10 as 10 598 NM_000141 IIIb+c CCACCATACAGGCGATTAAG
601 NM_022969 IIIb+c
607 NM_022972 IIIb+c
598 NM_022973 IIIb+c
601 NM_022974 IIIb+c
601 NM_022975 IIIb+c
607 NM_023028 IIIb+c
598 NM_023029 IIIb+c
601 NM_023030 IIIb+c
601 NM_023031 IIIb+c  
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FGFR 3 FGFR 3 Ex1 s 1 AGTCCTTGGGGACGGAGCA
FGFR 3 Ex5 as 5 672 NM_000142 alpha CCAGCACGTCCAGCGTGTA
672 NM_022965 alpha
FGFR 3 s 4 AACGGCAGGGAGTTCCGCGGC
FGFR 3 as 9 531 NM_000142 IIIb+c GTCAGCCTCCACCAGCTCCTC
FGFR 3 (B) Ex10 as 10 720 NM_000142 all variants GGACGCGTTGGACTCCAGGG
384 NM_022965 del.Ex9 TransDom.
FGFR 3 (B) Ex7 IIIb as 7 IIIb 429 Gudrun Vari. IIIb CCCGTCCCGCTCCGACACATTG
FGFR 3 (B) Ex8 IIIc as 8 IIIc 435 NM_000142 IIIc CCCGGCGTCCTCAAAGGTG  
 
 
FGFR 4 FGFR 4 (A) Ex2 s 2 TGCCTGGGCCTCCAGTCTTG
FGFR 4 (A) Ex5 as 5 486 NM_002011 Isoforms 1-3 CTGCAGCTGGACAGCGGAAC
486 NM_213647
486 NM_022963
597 AF_359241 Ezzat soluble
FGFR 4 (B) Ex6 s 6 AGCACTGGAGTCTCGTGATG
FGFR 4 (B) Ex10 as 10 766 NM_002011 Isoforms 1-3 CATAGTGGGTCGAGAGGTAG
766 NM_213647 Isoforms 1-3
766 AF_359246 ptd del Ex1-6
646 NM_022963 soluble del Ex9
FGFR 4 s 5 GATGGACAGGCCTTTCATGG
FGFR 4 as 9 525 NM_002011 Isoforms 1-3 TGCTGCGGTCCATGTGGGGTCCTC
525 NM_213647  
 
 
 
 
 
 
 
3.10 FGFR Splice Variants and PCR Fragments 
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SYBR-Green qRT-PCR Master Mix (1 x) Solution (Concentration) Volume (µl)
SensI Mix Plus (2 x Mix; Quantace) 10
Primer I (20 µM) 0.2
Primer II (20 µM) 0.2
Water bidest. 8.6
cDNA 1
20 total volume
 
 
 
 
 
 
 
 
Figure 3.1: Schematic Representation of splice variants of all four FGF-Receptors, including binding 
sites of used primers and expected PCR products. 
 
 
 
3.11 SYBR-Green quantitative RT-PCR (qRT-PCR) 
 
SYBR-Green Master Mix was prepared on ice. 1 µl cDNA was pipetted into two wells 
(per sample) of an Optical 96-Well Reaction Plate (Micro AmpR; Applied Biosystems). 
The master mix was added, and fluorescence was measured during PCR 
amplification by using an ABI Prism 7000 SDS thermocycler (ABI), according to ABI 
manuals. 
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TaqMan qRT-PCR Master Mix (1 x) Solution (Concentration) Volume (µl)
TaqMan Probes (Applied Biosystems) 0.625
TaqMan Master Mix (Applied Biosystems) 6.25
water bidest. 3.125
cDNA 2
12 total volume
3.12 TaqMan - “Real Time” quantitative RT-PCR (qRT-PCR) 
 
TaqMan Master Mix was prepared on ice. 2 µl cDNA was layered into two wells (per 
sample) of an Optical 96-Well Reaction Plate (Micro AmpR; Applied Biosystems), in 
case of 18S-rRNA, used for normalization, the cDNA was diluted 1:10. 10 µl Master 
Mix was added to a total volume of 12 µl, and mixed. PCR was performed and 
fluorescence measured after each cycle using an ABI Prism 7000 SDS thermocycler 
(ABI), according to ABI manuals. Taqman probes used in this study are listed in 
Table 3.3. 
 
 
 
 
 
 
 
 
 
 
Table 3.3: Used Taqman-Probes for FGFR 1-4. Binding 
sites and recognized isoforms are described on the 
company webpage (Applied Biosystems).  
 
 
 
 
3.13 Restriction Digest 
 
Restriction digestion was performed in a total volume of 20µl. Master Mix, including 
restriction enzyme and corresponding buffer (Fermentas), was prepared on ice. 15 µl 
of the PCR product was added first, followed by 5 µl Master Mix and mixing. 
Incubation time and temperature were usually one hour and 37°C, unless different 
conditions were required for the enzyme as stated by the supplier (Fermentas). 
 
 
 
 
 
Taqman-Probes FGFR1 Hs00915135_m1
FGFR2 Hs01552926_m1
FGFR3 Hs00179829m_1
Lot: 529030
Hs00997397m_1
FGFR4 Hs00608751g_1
Hs00608744g_1
Hs00242558_m1
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3.14 Gel Electrophoresis (Nucleic Acids) 
 
Nucleic acids, thus RNA and DNA, were separated on agarose gels of 0.5-2% (w/v), 
depending on fragment sizes. Typical sizes of 1-3 kilobases (kb) were separated on 
gels consisting of 1% agarose (Biozyme).  
 
Agarose was solubilised in 0.5 x TBE buffer (5.4 g/l Tris (Fluka), 2.75 g/l boric acid 
(Sigma) and 1 mM EDTA). In cases of desired high separation quality, nucleic acids 
were separated on poly-acrylamide gels ranging from 6-10% and run in 1 x TBE 
buffer. Samples were mixed with 6 x loading buffer (333 µl/ml 6 x loading dye 
(Fermentas), 250 µl/ml 80% glycerol (Merck), 66.5 µl/ml 0.5 M EDTA, 0.5 µl/ml 10 
000 x Vistra Green (GE Healthcare)) and loaded onto the gel. Depending on 
expected fragment sizes, different markers were loaded.  
 
Appropriate amounts of water and loading buffer were mixed with 2 µl of the 
respective marker. For agarose gels, 0.5 x TBE was used as running buffer and 1 x 
TBE for poly-acrylamide gels. Gels were run at constant voltage of 50 V for 10 min 
and raised afterwards to 120 V unitl the desired separation was achieved (gel 
apparatus: Bio-Rad). Fragment bands were visualized by FluorImager 595 Scanner 
from Molecular Dynamics. 
 
 
 
 
 
 
Master Mix 1 µl Restriction Enzyme
2 µl Buffer
2 µl Water dest.
Restriction Digestion 15 µl PCR Product
5 µl Master Mix
20 µl (Tot.Vol.)
8.5% (1 gel)
Poly-Acrylamid Gel Electrophoresis 2.4 ml 5x TBE
(Nucleic Acids) 3.45 ml 30% Acrylamid/Bis; 29:1 (Bio-Rad)
6.84 ml Water bidest.
100 µl APS
10 µl TEMED
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3.15 Isolation of Proteins 
 
For SDS-PAGE and Western-Blot analysis, all non-secreted proteins were isolated 
by using Lysis Buffer II (LBII). Cells were trypsinized and washed with cold PBS. 
Centrifugation was done at 800 rpm for 5 minutes. All successive steps were done on 
ice. Cells were lysed by adding LBII onto the cell pellet. Volume of lysis buffer 
depended on cell amount and usually ranged between 30 µl for around 500 000 cells 
and 120 µl for 2 million. The pellet was resuspended by pipetting up and down for 
several times, then the suspension was incubated for some minutes. Additionally the 
cell suspension was sonicated 3 times for 3 seconds (Bandelin). Insoluble 
components were removed by centrifugation at 4°C and 20 800 g for 10 minutes. 
Aqueous supernatant was transferred and stored at -20°C, for longer periods at -
80°C. 
  Protein Lysis Buffer II (FGFR3-IP): 
Stocksolution Final Concentration 1 Liter (+ bdH2O) 10 ml (+ bH2O) +  
1 Complete Tab. (Roche) 
100 mM EGTA 1 mM EGTA 10 ml 100 µl 
5 M NaCl 150 mM NaCl 30 ml 300 µl 
50 mM Na3VO4 1 mM Na3VO4 20 ml 200 µl 
100% Triton X 1% Triton X 10 ml 100 µl 
100 mM NaF 10 mM NaF 100 ml 1 ml 
1M Tris pH8 50 mM Tris 50 ml 0.5 ml 
 
 
 
 
3.16 Determination of Protein Concentration 
 
Protein isolations were subjected to Bradford Assay (Bio-Rad Protein Assay) to 
determine protein concentration (Simonian and Smith, 2006). Bradford solution (Bio-
Rad) was diluted 1:5 with water. Samples, as well as BSA for the calibration curve 
were placed (Table and Figure) into PS microplate 96-well (Greiner). Following this, 
190 µl of diluted Bradford solution was added and mixed, then incubated for around 
10 minutes at RT. Absorption of monochromatic light of 562 nm was determined 
using a SynergyHT plate reader (BioTEK) and Gen5 software (BioTEK). Protein 
concentration of samples was finally calculated from the calibration curve (Figure 3.2 
and Table 3.4). Obtained concentrations had to be multiplied by 10, because of the 
1:10 dilution of samples. 
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Table 3.4: Pipetting Scheme of BSA standards and protein samples.  
All concentrations were calculated by taking the average of double determinations. 
 
 
Calibration Curve
y = 0,5238x + 0,1499
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Figure 3.2: Example of calibration curve used for determination of protein concentration by 
Bradford Assay. 
 
 
3.17 SDS-Polyacrylamid Gel Electrophoresis 
 
For Western Blot (Gallagher, Winston et al., 2008) analysis, protein samples were 
subjected to SDS-PAGE (Gallagher, 2007) first. The Mini Protean 3 system (Bio-
Rad) was used for protein separation. Discontinuous poly-acrylamide gels were 
generated (Table 3.5), with densities between 7.5 and 15% according to protein sizes 
desired to be investigated. The high density separation gel was cast and topped with 
isopropanol. After polymerization, the isopropanol layer was rinsed off with water and 
removed with filter (Schleicher and Schuell). Afterwards, the stacking gel was cast on 
top and sealed with a ridge. Following polymerization, the ridge was removed and 
pockets were cleaned with SDS Running Buffer (25 mM Tris, 192 mM glycin and 
0.1% SDS), which was also used as running buffer for SDS-PAGE.  
Water (µl) Lysis-Buffer (µl) BSA (1 µg/µl) Conc. (µg/µl) Samples (µl)
blank 9 1 0 0
1 8 1 1 0.1
2 7 1 2 0.2
3 5 1 4 0.4
4 3 1 6 0.6
5 1 1 8 0.8
6 0 1 9 0.9
9 1
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Separation Gels 7,50% 10% 12% 15% Volume
Water 2.379 1.960 1.625 1.122 ml
1.6 M Tris pH 8.8 1.250 1.250 1.250 1.250 ml
20% SDS 50 50 50 50 µl
30% Acrylamid/Bis; 29:1(Bio-Rad) 1.256 1.675 2.010 2.513 ml
10% APS (Merck) 25 25 25 25 µl
TEMED (Amresco) 5 5 5 5 µl
Stacking Gel 4% Volume
Water 1.5 ml
0.5 M Tris pH 6.8 0.625 ml
20% SDS 12 µl
30% Acrylamid/Bis; 29:1(Bio-Rad) 0.325 ml
10% APS (Merck) 25 µl
TEMED (Amresco) 2.5 µl
Usually 20 µg of protein lysate was mixed with 5 x SDS-PAGE Loading Buffer, 
denaturated for 5 minutes at 95°C and loaded into the gel pocket. Additionally, 5 µl of 
Page Ruler Plus Prestained Protein Ladder (Fermentas) was loaded as marker. Gels 
were run at a voltage of 50 V, until tracking dye (bromphenolblue) reached the 
separation gel, then was increased to 110 V.  
 
Table 3.5: Recipes for PAGE gels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
 
3.18 Western Blot 
 
Proteins separated by SDS-PAGE were transferred onto a PVDF membrane 
(Hypond-P, GE Healthcare) for immunodetection with specific antibodies. The Mini 
Protean 3 system was used for blotting. The transfer procedure was done according 
to the tank transfer protocol (Gallagher, Winston et al., 2008). First, the PVDF 
membrane was activated with methanol, rinsed with water and equilibrated in Towbin 
Buffer (25 mM Tris, 192 mM glycin, 5% MeOH), also used as transfer buffer. The 
blotting sandwich was assembled, and transfer was performed at a voltage of 18 V, 
overnight in the fridge (4°C). In rare cases, the transfer was done for 2 hours at 4°C 
and with an additional -20°C cooling pack in the tank, at a current of 200 mA. The 
PVDF membrane was rinsed with water. Quality of transfer was controlled by staining 
protein bands with Ponceau S Solution (0.5 g/l  Ponceau S (Sigma) and 1 ml/l glacial 
acetic acid (Gallagher, Winston et al., 2008). The membrane was incubated in the 
staining solution for about 5-20 minutes, then the background was removed by 
washing with distilled water, on the shaker. To increase quality, water was changed 
several times. Afterwards, the staining was documented using a photocopier. 
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For immune-staining, the membrane was re-activated by short incubation in 
methanol, was washed in water and blocked in TBST-M (TBS: 8 g/l NaCl, 0.2 g/l KCl, 
3 g/l Tris, pH 7.4; T: 0.1% Tween 20 (Sigma); M: 5% Skim Milk Powder (Fluka) for 1 
hour at RT, on the shaker. Blocking solution was washed off 3 x 5 minutes with 
TBST. The membrane was placed into a 50 ml Falcon tube, protein bands oriented 
towards the inside, and incubated in at least 5 ml of Primary Antibody Solution (Table 
3.6), overnight on a rotator in a 4°C room. Next day, the membrane was washed 3 x 
with TBST and incubated in the Secondary Antibody Solution, for 1 hour on the 
shaker at RT. PVDF membrane was washed again, 3 x with TBST and 2 x with TBS, 
then incubated upside down on a parafilm with Immune-Star WesternC reagent (Bio-
Rad) and visualized using Hyperfilm ECL (GE Healthcare). 
 
Table 3.6: List of antibodies used for immune-detection. Concentration of BSA as diluent was 3%, but 
for milk powder (M) was 5%.  
 
. 
 
 
3.19 Lipofection 
 
3 x 105 cells were seeded into 6-well plates with 2 ml RPMI medium (+10% FBS) and 
incubated overnight. Next day, cells were adherent and around 50-80% confluent. As 
lipofection reagent either FuGENE 6 or FuGENE HD was used (both from Roche). 
Considering toxicity and lipofection efficiency, both reagents showed similar results.    
Primary Antibodies Dilution Supplier Diluent Size of Target
Mouse-anti-GFP 1:2000 Roche; 11814460001 M 27 kDa
Rabbit-anti-pAkt (Ser 473) 1:1000 Cell Signaling; 9271 BSA 60 kDa
Rabbit-anti-pAkt (Thr 308)) 1:1000 Cell Signaling; 4056 BSA 60 kDa
Rabbit-anti-Akt 1:1000 Cell Signaling; 9272 BSA 60 kDa
Rabbit-anti-pFRSalpha (Tyr 196) 1:1000 Cell Signaling; 3864 BSA 85 kDa
Mouse-anti-pERK 1:1000 Sigma; M8159 BSA 44/42 kDa
Mouse-anti-ERK 1:1000 Cell Signaling; 9101 BSA 44/42 kDa
Rabbit-anti-pS6 1:1000 SAB; 11232-2 BSA 32 kDa
Rabbit-anti-S6 1:1000 SAB; 21225-2 BSA 32 kDa
Rabbit-anti-FGFR4 (C16) 1:1000 Santa Cruz; sc124 M 125 kDa
Mouse-anti-Cytochrom C (A-8) 1:1000 Santa Cruz: sc13156 BSA 16 kDa
Rabbit-anti-PARP-1 1:1000 Cell Signaling; 9542 BSA 24, 89, 116 kDa
Cleaved PARP-1 1:1000 Cell Signaling; 9541 BSA 89 kDa
Rabbit-anti-Caspase-3 1:1000 Cell Signaling; 9662 BSA 17, 19, 35 kDa
Rabbit-anti-pSTAT-3 1:1000 Cell Signaling; 9134 BSA 79, 86 kDa
Mouse-anti-ß-actin 1:5000 Sigma M 45 kDa
Secondary Antibodies Dilution Supplier Diluent Size of Target
Rabbit-anti-Mouse-HRP 1:10 000 Dako; P0260 M n/a
Goat-anti-Rabbit-HRP 1:10 000 Dako; P0448 M n/a
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Transfection reagent (3 µl) was added directly to 97 µl Serum Free Medium (SFM; 
RPMI without FBS) and mixed. After 5 minutes incubation time, 1 µg plasmid was 
added, mixed and incubated for another 25 minutes. In case the plasmid did not 
contain a desired selection marker, a second plasmid possessing the specific marker 
was added, thereby performing a co-transfection.  
The total volume of transfection suspension was droped onto the medium containing 
adherent cells (2 ml/well of a 6-well plate) and gently mixed. The following day, 
lipofected cells were expanded into 10 cm tissue culture dishes, thereby medium was 
changed, and incubated for another 24 hours. Then the standard growth medium 
was changed to selection medium containing antibiotics, according to the used 
resistance gene (See Selection of Stable Transfectants). 
 
 
3.20 Selection of Stable Transfectants 
 
Cells integrating selection marker and hopefully the gene of interest into their 
genome, were seen as stably expressing cell lines. All plasmids used, contained 
either a neomycin resistance gene or a puromycin resistance gene, therefore stable 
transfectants were selected with G418 / neomycin or puromycin (Table 3.7). To 
reduce the risk of the fake clone phenomenon, where only selection markers are 
expressed but not the gene of interest, some plasmids coded for bicistronic mRNA 
with these two genes separated only by an IRES (Internal Ribosomal Entry Site; 
Gurtu and Yan et al., 1996). However, all generated cell lines were tested for 
expression of the respective genes of interest by Western Blot analysis or Immuno-
histochemistry (IHC) and qRT-PCR. 
 
Selection medium was changed several times, facilitating perfect growth conditions. 
When resistant clones appeared, usually after 1-2 weeks, clones were picked and re-
seeded. New cell lines were frozen and tested for expression, as soon as possible, to 
reduce the risk of losing clones due to contamination. Besides, all selection media 
contained also penicillin and streptomycin to prevent bacterial infections. 
 
Table 3.7: End-concentration of additives during selection and cultivation. 
G418 (PAA) Puromycin (PAA) Doxocyclin
Concentration (µg/ml) 300 0,4 0,1  
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3.21 Adenoviral Transduction 
 
3 x 105 cells were seeded into 6-well plates with 2 ml RPMI medium (+10% FBS) and 
incubated overnight. The following day viral suspension was added drop-wise onto 
the medium and the plates shaked gently. Cell lines were transduced at different MOI 
(Multiplicity Of Infection). Adenoviruses were diluted and the appropriate volume was 
calculated according to the ifu / µl (infectious units per µl) of viral stocks.  
 
3.22 Viability Assay 
 
Cell lines (105 cells per 6-well) were transduced by adenoviruses containing different 
dominant-negative receptor constructs (dnFGFRs). The day after transduction, cells 
were trypsinzed and counted. Following different incubation times, varying between 
one and six days, cells were trypsinzed and counted again (Casy Cell Counter). 
Additionally, the proliferation was monitored by microscopy and Höchst 
33258/propidium iodide staining. For cell staining, all cells of a well (6-well plate), 
including those in the supernatant, were collected and centrifuged. The cell pellet 
was taken up in 99 µl medium and 1 µl staining solution was added, thereby diluted 
1:100. After 30 minutes of incubation, numerical ratio of viable versus apoptotic cells 
was counted under the microscopy.    
 
 
3.23 Soft Agar Assay 
  
Cells were washed (PBS), trypsinized and counted. Appropriate volume, containing 
30000 cells, was centrifuged (800 rpm for 5 minutes) and the pellet was taken up in 
750 µl Soft Agar Medium, having a temperature of 37°C. 750µl 1% Agar Solution (40-
41°C) was added to the cell suspension and mixed. A total volume of 1.5 ml was 
added on top of solid soft agar and resulted in a total volume of 3 ml (0.5% solid soft 
agar medium) per well, of a six well plate. Solutions were kept on temperature in the 
water bath. To reduce velocity of temperature reduction, solutions were put into a 
tray containing warm water during pipeting. After the desired clone size was reached 
(>30 µm), the number of clones above a specific threshold level was counted under 
the microscope, e.g.: clones larger than 30 µm. The clone size was calculated using 
Metamorph software.   
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Soft Agar Medium, as well as 1% Agar Solution, were prepared the day before, as 
follows. Considering the Soft Agar Medium, 2ml NaHCO3 (110 mg/ml, in water 
bidest.), 1 ml glutamine, 17 ml water (bidest.) and 50 µl folic acid were added to 10 
ml (10 x) RPMI medium (Sigma). The solution was brought to a pH value of 8 and 
sterile filtered. Then, 20 ml FCS and 1ml penicillin-streptomycin were added under 
sterile conditions. For subsequent generation of the soft agar bottom, the medium 
was brought to a temperature of 37-40°C. For preparation of 1% Agar Solution, 1.2 g 
agar was added to 80 ml water (bidest.) and solubilised by boiling. Simultaneously 
another 30 ml of water (bidest.) were heated up and used to fill up the 80 ml 
suspension to 100 ml. At the end the suspension was boiled again. Afterwards, the 
solution was brought to a temperature of about 40°C, for subsequent generation of 
the soft agar bottom. 
 
Soft Agar Medium and 1% Agar Solution were mixed 1:1. 1.5 ml were subsequently 
pipetted into each well of a six well plate, constituting the soft agar bottom. Air 
bubbles were prevented by leaving a low amount of solution in the pipette. 
Afterwards, plates were put in the fridge until the agar became solid, then were put 
into the incubator over night. 
 
 
3.24 Clonogenic Assay 
 
1000-3000 cells were seeded into one well of a six well plate containing 2 ml RPMI 
medium (10%). After the desired clone sizes (>1 mm) was reached, depending on 
specific clonogenicity of the cell line used, cells were stained with crystal-violet. The 
number of clones above a specific threshold size was counted, e.g.: all clones larger 
than 1mm in diameter. 
 
3.25 Crystal-Violet Staining 
 
Supernatant was discarded, cells were washed in PBS and fixed by incubation in 
methanol : acetone (1:1) for about 20 minutes. Then cells were exposed to crystal-
violet solution, diluted 1:1000 in PBS (stock: crystal violet in PBS and 10% ethanol) 
and incubated for another 20 minutes. Staining solution was discarded and cells 
were air dried over night. 
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3.26 Migration Assay 
 
To test for cell migration and invasion, transwell-chambers in a 24 well-plate format 
were used. 40000 cells in 200 µl medium were seeded onto porous membranes, 800 
µl medium were added into the well resulting in a total volume of 1 ml. The RPMI 
medium used, contained 4% FCS. As control, migration of untreated cells was tested 
in RPMI medium including 10% FCS. Migration through the membrane pores was 
visualized by crystal-violet staining. Incubation times ranged from 24-72 hours.  
 
 
3.27 MTT Assay 
 
To test cell proliferation, 3000-5000 cells were seeded in 100 µl RPMI medium (10% 
FBS) into one well of a 96 well-plate. Suggested inhibitor or stimulator molecules 
were added as (2 x) concentrations in 100 µl serum-free medium, resulting in a total 
volume of 200 µl (5% FBS). Inhibitors were added 24 hours after seeding, while 
putative stimulators were added already after around 3 hours. Incubation times 
ranged between 3-5 days. For determination of cell concentration the MTT kit EZ4U 
from Biomedica was used according to the manufacturer´s protocol. Cells were 
incubated at 37°C and 5% CO2 for 2-5 hours. Absorption was measured at 450 nm 
and 620 nm as reference using a Synergy spectrophotometer.  
 
3.28 Tumour Growth in SCID Mice 
 
Cell lines were seeded in 10% RPMI and incubated over night. The following day, 
cells were transduced with adenoviruses bearing dominant-negative FGFR 
constructs, according to suggested MOIs. After 24h incubation, 106 cells in 50 µl 
serum free medium were injected subcutaneously into the flanks of SCID mice. 
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4 Results 
 
4.1 Expression Analysis of FGF-Receptors and Isoforms 
 
RT-PCR of the major isoforms of FGFR 1-4 was performed in 12 cell lines derived 
from primary tumours or metastases of different histological types of melanoma. 
Primary melanocytes were included for comparison. Considering the investigated 
splice variants, alpha isoforms possess IgG-I domains, while beta variants do not. 
IgG-IIIb and –IIIc isoforms differ in sequence within the second, C-terminal part of the 
IgG-III domain. Additionally it has been shown, that the IIIb domain is predominantly 
expressed in cells derived from the epithelial cell lineage, while mesenchymal 
derived cells tend to express the IIIc domain. The isoform named beta acidic box 
possesses an alternative amino acid sequence within the IgG-II domain. Soluble 
stands for isoforms not containing transmembrane domains, thus will not integrate 
into the cell membrane. Isoform-1 and -3 of FGFR-4 encode the same protein and 
differ only in the used splice site for exon 1. Isoform 2-soluble has no transmembrane 
domain, in contrast to isoform-1 and-3. The isoform named ezzat soluble consists 
only of the IgG-I domain and a 3`UTR region (Table 4.1).  
 
Table 4.1: Expression analysis of FGF-Receptors, including different splice variants, by standard 
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR). From left to right: FGFR 1-4, Splice 
Variants, 12 Vienna Melanoma Cell Lines (Number and Trivial-Name) and Primary “Non-transformed” 
Melanocytes (PM) as reference.  
 
VM 1 VM 7 VM 8 VM 10 VM 21 VM 23 VM 24 VM 28 VM 30 VM 31 VM 47 VM 48
FGFR Splice Variant FTSL/A GTBS GUBS/A JMUM RHTP RKTJ SHTJ TMFI WCRE WLTJ HOST KAKA PM
1 alpha + + + + + + + + + + + + +
beta + + + + + + + + + + + + +
IIIb + + + + + + + + + + + + +
IIIc + + + + + + + + + + + + +
2 alpha + + + + + + + - - + + + +
beta - + + + - + + - - + + + -
beta acidic box + + - - + - - - + + + + +
IIIb + + - + + + + - - - + + +
IIIc - + - + - + + - - + + + +
3 alpha + + + + - + + - - - + + +
IIIb - - - + + + + + + + + + +
IIIc - + - + + + + + + - + + +
soluble - + - + + + + + + + + + +
4 isoform 1+3 + + + + + + + + + + + + +
isoform 2-soluble - - - - + + + - + - + + +
ezzat soluble + + + + - - + - - + - + +
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Isoforms consisting of all three IgG-domains, transmembrane domain and tyrosine 
kinase domain of FGFR-1 and FGFR-4 were expressed in all cell lines and primary 
melanocytes, whereas FGFR-2 and FGFR-3 isoforms were absent in some of the 
melanoma cell lines. This indicates the great importance of FGFR-1 and FGFR-4. 
What`s more, all alternative splice variants of FGFR-1 investigated in this study, were 
detected in 100% of our cell lines. Considering isoforms of FGFR-2 and FGFR-3, the 
expression pattern seems to be quite heterogeneous. What might be surprising is, 
that all FGFR isoforms investigated, were also detected in our primary melanocytes, 
apart from the FGFR-2 beta isoform. This indicates the possibility, that the FGFR-2 
beta isoform, might be a potent regulator for melanocytic to melanoma transition, 
although this has to be clarified in further experiments. At this point one has to 
consider, that primary melanocytes used as reference in all expression experiments 
are of embryonal and not adult origin. In general, all splice variants seem to be 
expressed in low amount and in a heterogeneous manner, considering all malignant 
cell lines as well as non-transformed melanocytes. 
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Figure 4.1: Relative expression of FGF-Receptors in all 12 VM Cell Lines and Primary Melanocytes (PM), determined by 
quantitative Reverse Transcriptase Polymerase Chain Reaction (“Real Time” qRT-PCR). Values shown in the figure were 
calculated using the formula: 2^(-dCT)*100 000. Determined CT-values were normalized to 18S-rRNA expression.  
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Figure 4.2: FGF-Receptor expression in comparison to Primary Melanocytes (PM). Analysis was performed by 
quantitative RT-PCR and values were calculated by the formula: 2^(-ddCT). For each receptor, the expression 
level in primary melanocytes was set as 1. 
 
 
Expression analysis by qRT-PCR revealed, that FGFR-1 and FGFR-4 are highly 
expressed in nearly all malignant melanoma cell lines, compared to FGFR-2 and 
FGFR-3. Considering the FGFR expression in non-transformed melanocytes, it is 
shown, that only FGFR-1 is highly expressed. Taking non-transformed melanocytes 
as reference, the expression of FGFR-4 and FGFR-2 seems to be highly up-regulated 
in nearly all malignant melanoma cell lines, while high expression of FGFR-1 is 
maintained and expression of FGFR-3 stays low (Figure 4.1 and 4.2). In general, 
results from quantitative analysis correlated well with band intensities, observed by 
standard PCR. Expression pattern of a given FGF-receptor is heterogeneous among 
all investigated melanoma cell lines and seems not to be specific for a specific tumor 
stage or metastasis type (Figure 4.3). 
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Figure 4.3: Relative expression of FGF-receptors analysed by “Real Time” qRT-PCR in melanoma cell lines grouped by tumor stage (primary tumour 
versus metastasis) and organ localization of metastases .  PM: Primary Melanocytes; PT: Primary Tumour; LN: Lymph Node Metastases; BR: Brain 
Metastases; ME: Malignant Effusions. 
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4.2 Expression Analysis of Fibroblst Growth Factors 
  
FGF-1 and FGF-2 were found to be expressed in nearly all cell lines including primary 
melanocytes. FGF-5 was shown to be expressed in the majority, and FGF-18 in all cell 
lines. These two factors were recently reported as oncogenic in different tumour 
tissues, therefore expression levels were analysed by qRT-PCR. FGF homologue 
factors (FGF11-14), were found to be expressed in nearly all cells. However, it was 
recently shown, that these are not able to bind FGFR, despite their structural homology 
(Table 4.2).  
 
Table 4.2:  FGF expression analysis, of all 22 FGFs in twelve different melanoma cell lines and primary 
melanocytes. FGF-15 is the mouse ortholog of FGF-19, therefore is not shown in the table. 
 
 
Quantitative expression analysis revealed, that FGF-2 is highly up-regulated in all 
melanoma cell lines (100%) investigated, the long isoform as well as the short isoform 
of FGF-5 was up-regulated in the majority (90%) and the short isoform was found to be 
4 times less expressed, compared to the long version, in all cell lines. Expression of 
FGF-18 was up-regulated in around 40%, while expression of FGF-17 and FG-F8 
stayed low (Figure 4.4). In general, these results correlate with those obtained by 
standard PCR.  
 
 
 
 
 
 
VM 1 VM 7 VM 8 VM 10 VM 21 VM 23 VM 24 VM 28 VM 30 VM 31 VM 47 VM 48
FTSL/A GTBS GUBS/A JMUM RHTP RKTJ SHTJ TMFI WCRE WLTJ HOST KAKA PM
FGF1 + + + + - - + + + + + + +
FGF2 + + + + + + + + + + + - +
FGF3 - - - - - - - - - - - - -
FGF4 - - - - - - - - - - - - -
FGF5 + + + - - + + - + + + + -
FGF6 - - - - - - - - - - - - -
FGF7 - - - - - - - - - - - - -
FGF8 - - - + - - + - - - - + -
FGF9 - - - - - - - - - - - - -
FGF10 - - - - - - - - - - - - -
FGF11 + + + + + + + + + + + + +
FGF12 - + - + + + + - + + + + -
FGF13 + + + + + + + + + + + + +
FGF14 + + + - - + + - + + - - +
FGF16 + + + - + + - + - + - - +
FGF17 - - - - - - - - - - - - -
FGF18 + + + + + + + + + + + + +
FGF19 - - - - - - - - - - - - -
FGF20 - + - + - - - - - - - + -
FGF21 + + - - + + - - - + - - +
FGF22 + + + + - + + - - - + + +
FGF23 + + - + - - + - - - - + -
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Figure 4.4: Quantitative expression analysis (qRT-PCR) of selected FGFs. Cell lines derived from metastases were 
stratified according to their tissue origin. Relative values were calculated by the formula: 2^(-dCT)*100 000. Thus primary 
melanocytes were used for comparison but were not used as calibrator. 
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4.3 Analysis of Cellular Effects by Blockade of Different FGFRs 
by Dominant Negative Receptor Constructs 
 
 
Four melanoma cell lines were infected with adenoviruses bearing different dominant-
negative FGFR constructs. Considering dnFGFR1 adenoviruses, the sequence coding 
for the kinase domain was replaced by GFP, in case of dnFGFR4 it was replaced by 
CFP. For the kinase-dead FGFR3 (kdFGFR3) construct, a mutation was introduced 
leading to a non-functional kinase domain. As controls, adenoviruses expressing GFP, 
instead of dnFGFR, were used. All viruses were available in the FGF research 
cooperation of the ICR from previous investigations. 
 
 
    
 
 
 
 
 
   MOI: 1                                        MOI: 15                                       MOI: 200 
   
 
 
 
 
 
 
    MOI : 20                                     MOI : 100                                    MOI : 200 
Figure 4.5: Fluorescence microscopy of melanoma cells (FTSL-A; VM1), five days after transduction 
with adenoviruses containing GFP and dnFGFR4-CFP constructs, at different MOIs.    
 
 
 
The most difficult part was to find appropriate MOIs (Multiplicity Of Infection) for the 
transduction procedure. This was optimized by infection of cell lines at different MOIs 
and subsequent analysis by microscopy (Figure 4.5 and 4.6), monitoring fluorescence 
and toxicity, as well as by Western-Blot (Figure 4.7). The aim was to choose 
appropriate MOI values leading to equivalent episomal protein expression of all 
adenoviral constructs. Expression of dnFGFRs and GFP was visible already 24h after 
infection. Cell toxicity of adenoviruses was tested up to an MOI of 60.  
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 GFP                                            dnFGFR1-GFP                             dnFGFR4-CFP 
 
 
 
 
 
 
 
 
 
 MOI: 2                                         MOI: 5                                         MOI: 30 
Figure 4.6: Microscopy of melanoma cells (SHTJ; VM24), three days after adenoviral infection. From 
left to right: Transduced with GFP at MOI: 2; dnFGFR1-GFP at MOI: 5; dnFGFR4-CFP at MOI: 30. 
 
All cells visibly expressing dnFGFR1-GFP and dnFGFR4-CFP were small, round 
shaped and seemed to undergo apoptosis (Figure 4.6 and 4.8). This gave a first 
impression of the importance of the FGFR signalling pathway for melanoma cell 
survival.  
 
 
                                                 MOI:         20                100                200  
  
  
                                        RHTP 
 
  
 
 KAKA  
 
 
  
 SHTJ 
 
  
 
 FTSL-A 
 
 
Figure 4.7: Western Blot analysis of four different 
cell lines transduced with adenoviruses 
containing the dnFGFR4-CFP construct. Cells 
were incubated five days, proteins were isolated 
and dnFGFR4-CFP expression was analysed 
using anti-GFP antibodies. Protein 
concentrations were equalized prior to loading to 
20 µg. 
 
 
Ectopic expression of dnFGFRs seems to be cell line dependent (Figure 4.7 and 4.8), 
with highest expression achieved in FTSL-A (VM1) and lowest in KAKA (VM48). 
Results from Western Blot analysis, were also confirmed by microscopy. Our objective 
was to achieve equal expression of all dnFGFRs including GFP control by working with 
appropriate MOIs. However, this required higher MOIs for dnFGFR adenoviral 
infections, compared to the GFP control.  
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This leaves the possibility of cell toxic effects caused by the virus itself. It was shown 
however, that transduction of cells with adenoviruses containing GFP constructs, did 
not show visible cell toxic effects up to MOI: 5. At an MOI of 30 or higher, cell 
proliferation was reduced around 15%, compared to MOI: 2 (Figure 4.10 and 4.11).  
 
 
   
 RHTP              KAKA   
 
 
 
 
 
 
 
 
 
 SHTJ                FTSL-A 
 
 
 
  
 
 
 
 
 
Figure 4.8: Microscopy of four melanoma cell lines transduced with 
adenovirus containing dnFGFR4-CFP constructs at MOI: 100. It is 
obvious, that expression is dependent on the cell line. These results also 
correlate with Western Blot analysis shown above. 
 
 
 
The intensity of fluorescence, observed during microscopy, highly correlated with 
protein expression analyzed by immune-detection (Figure 4.7, 4.8 and 4.9). This 
implies, that dnFGFR1-GFP is less expressed compared to GFP, although cells were 
infected with an MOI of 5 considering dnFGFR1-GFP and an MOI of 2 considering GFP 
viruses (Figure 4.9). This is also the case for dnFGFR4-CFP expression. Although cells 
were infected with an MOI of 30 the fluorescence is low, and at protein level expression 
is even below the limit of detection, in three of four cell lines. 
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                   GFP        dnFGFR1    dnFGFR4     
   
 
 
 
  
 
 
 
 
 
 
 
 
Figure 4.9: The melanoma cell line 
FTSL-A was infected by 
adenoviruses containing dnFGFR 
and GFP constructs. After five days 
of incubation expression levels were 
analysed by Western Blot. 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Microscopy of GFP adenoviral 
transduced FTSL-A cells, after 48 hours incubation 
time. Cells were transfected at different MOI, after 
24 hours 105 cells were seeded into a 6-well plate. 
Pictures were taken after 48 hours incubation time. 
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Finally, we decided to take MOIs ranging from 2 to 30. GFP control adenoviruses were 
used at MOI: 2, dnFGFR1-GFP adenoviral constructs at MOI: 5, and kdFGFR3 and 
dnFGFR4-CFP constructs at MOI: 30. It was shown, that protein expression of 
dnFGFR1-GFP, kdFGFR3 and dnFGFR4-CFP was far below GFP control, although 
much higher MOIs were applied. What has to be taken into consideration is, that viral 
induced cell toxic effects reduced cell proliferation about 15% at MOIs of 30. The MOI 
of 5, applied for dnFGFR1-GFP adenoviruses, did not show cell toxic effects (Figure 
4.10 and 4.11), when used for GFP transduction.  
 
Figure 4.11: Proliferation assay of GFP adenovirus transduced FTSL-A 
(VM1) melanoma cells, after 48 hours incubation time. Cells were 
transfected at different MOI, after 24 hours 10^5 cells were seeded into 
a 6-well plate. Cell number was determined by Casy Cell Counter after 
48 hours. Experiment was done in triplicates, and monitored by 
microscopy. 
 
 
 
4.3.1 Viability Assays 
 
Cell lines were infected with adenoviruses containing dnFGFR constructs and GFP 
control construct, incubated overnight, and seeded at low cell densities the following 
day. Cell proliferation was measured after two (48 h) and five days (120 h) using 
spectroscopic and staining methods. Cells were stained with Höchst and propidium-
iodide solution and subsequently counted under the microscope. In addition, cell 
concentration was measured using the Casy Cell Counter.  
 
Used MOIs, for adenoviral infections, were: MOI: 2 for GFP, MOI: 5 for dnFGFR1-GFP 
and MOI: 30 for dnFGFR4-CFP as well as for kdFGFR3 viruses. 
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Figure 4.12: Proliferation of melanoma cell lines (FTSL-A/VM1; KAKA/VM48; SHTJ/VM24; RHTP/VM21)  
infected with adenoviruses containing dnFGFR constructs and GFP control construct. Percent of total 
cells, taking the GFP control as reference. Cells were incubated 48 hours.  
 
 
 
 
Results clearly show the impact of the FGFR-1 mediated FGF-signalling pathway on 
cell proliferation (Figure 4.12 and 4.15), and apoptosis (Figure 4.13 and 4.14). Although 
the dnFGFR1-GFP protein was shown to be less expressed, it leads to a decrease of 
cell proliferation of around 50%, compared to the GFP control. What`s more, inhibition 
of the FGFR-4 and FGFR-3 mediated pathway, also decreased cell proliferation around 
20-30%, although fluorescence of the dnFGFR4-CFP protein was barely visible and 
both proteins could not be detected by Western Blot analysis, thus are suggested to be 
expressed in low amounts.  
 
However, cells transfected with kdFGFR3 and dnFGFR4-CFP viral constructs were 
transduced at MOIs of 30. This high MOI was shown to be anti-proliferative even when 
only GFP was transfected, thus suggesting reduced proliferation of around 15% by the 
virus itself. Therefore, it is suggested that anti-proliferative effects of kdFGFR3 and 
dnFGFR4-GFP are much lower than 20-30%. MOIs of 5 did not affect cell proliferation 
when transfected with GFP viruses (Figure 4.11), thus around 50% reduction in 
proliferation is indeed caused solely by the dnFGFR1-GFP protein and, presumably its 
down-regulation of the FGFR-1 signalling pathway (Figure 4.15).  
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Figure 4.13: Percentages of “non-viable” cells, apoptotic or 
necrotic, as determined by the Casy Cell Counter. The average of 
all four melanoma cell lines tested is shown. 
 
 
 
 
 
 
                GFP     
 
 
 
 
 
 
 
 
 
 
 
   dnFGFR4-GFP 
 
 
 
 
 
 
 
 
 
 
Figure 4.14:  Example of melanoma cell line (KAKA; VM48) stained with propidium 
iodide. Cells were infected with adenoviruses containing dnFGFR constructs, 
incubated for two and five days, trypsinized and stained. Left pictures show total 
cells, viable and dead or apoptotic cells (“non-viable”), as well as cell fragments. 
Stained cells, shown on the right side, were counted as dead or apoptotic. These 
cells still possess a membrane, thus their cytoplasm is enclosed, but the cell 
membrane has become porous, therefore is no longer a barrier for the staining 
solution (red spots). 
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Cell number can be reduced in two ways, either by inducing apoptosis or by decreasing 
cell division. Results suggest, that by inhibition of the FGF-signalling pathway, cell 
number is likely to be reduced by both options. Considering inhibition of the FGFR-1 
mediated pathway, around 6% more dead cells were found, in contrast to the GFP 
control. Thus, apoptosis seems to increase, when the FGF signalling pathway is 
inhibited. However, it is unlikely, that the observed impact on cell proliferation is only 
achieved by induction of apoptosis.  
The amount of cells, detected as necrotic or apoptotic by the Casy Cell Counter (Figure 
4.13), was verified by propidium-iodide staining (Figure 4.14). All red stained cells were 
counted as “non-viable” or dead and compared to the total number of cells.  
Propidium-iodide  is an intercalating agent and a fluorescent molecule that can be used 
to stain DNA. When excited by 488 nm of laser light, it can be detected with 562-588 
nm band pass filter. It can be used to differentiate necrotic, apoptotic and viable, thus 
normal cells. It binds to DNA by intercalating between the bases with little or no 
sequence preference and once the dye is bound to nucleic acid, its fluorescence is 
enhanced 20-30 fold, fluorescence excitation maximum is shifted around 30-40 nm to 
the red and fluorescence emission maximum is shifted around 15 nm to the blue. 
Propidium-iodide is membrane impermeant and generally excluded from viable cells, 
thus is commonly used for identifying dead cells among a given population (Moore A, 
2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15: Microscopy of VM1 cells, infected with adenoviruses containing 
eigther GFP or GFP tagged dnFGFR1 constructs, after 48 hours. 
 
 
 
 
 
GFP 
dnFGFR1-GFP 
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Beside propidium-iodide staining and fluorescence microscopy (Figure 4.14 and 4.15), 
induction of apoptosis by FGFR-1 inhibition was also verified by Western Blot analysis 
(Figure 4.16).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Induction of apoptosis in FTSL-A (VM1) cells transduced with 
GFP, dnFGFR1-GFP, kdFGFR3, dnFGFR4 adenoviruses, analysed by 
Western Blot. NC was an untransfected control. Likewise treated cells were 
used for in vivo growth by xenotransplantation experiment in SCID mice. 
Cells were re-seeded and proteins were isolated around one week after 
viral transduction.. 
 
PARP1 (Poly ADP-Ribose Polymerase 1) is a chromatin-associated enzyme and 
modifies various nuclear proteins by poly-ADP-ribosylation. The modification is 
dependent on DNA and is involved in the regulation of various important cellular 
processes such as differentiation, proliferation, tumour transformation and molecular 
events involved in DNA repair. It has been shown, that PARP1 is cleaved when 
apoptosis is induced, thus the protein is also used as apoptotic marker (Ha HC, 2000).  
 
The caspase 3 enzyme is a member of the cysteine-aspartic acid protease (caspase) 
family. Sequential activation of caspases plays a central role in the execution-phase of 
cell apoptosis. Caspases exist as inactive pro-enzymes that undergo proteolytic 
processing at conserved aspartic residues to produce two subunits, large and small, that  
dimerize to form the active enzyme. The protein cleaves and activates caspases 6, 7 
and 9, and is itself processed by caspases 8, 9 and 10 (Suzuki Y, 2001). As shown in 
(Figure 4.16) cleaved PARP1 and reduction of unprocessed caspase 3 are seen in 
dnFGFR1 transduced VM1 cells indicating induction of apoptosis. 
 
 
 
 
 
 
 
 
78 | P a g e  
 
 
4.3.2 Clonogenic Assays 
 
Melanoma cells were tested for their ability to survive and form clones, when seeded at 
very low density. After desired clone sizes were reached, depending on specific 
clonogenicity of the cell line, cells were stained with crystal-violet. Numbers of clones 
were determined by counting the clone number above a specific threshold level, e.g.: 
all clones larger than 1mm in diameter. 
 
 
 
                       VM48 
 
 
 
 
 
 
             GFP                                    dnFGFR1 
 
  VM21 
 
 
 
 
 
 
 
                      GFP                                    dnFGFR1 
Figure 4.17: Example of two melanoma cell lines (VM48 and VM21) 
transduced with adenoviruses containing GFP or dnFGFR1-GFP 
constructs. Cells were infected, incubated for 24 hours, then seeded 
at low densities (3000 cells/well). Two independent experiment were 
performed. 
 
 
 
Results showed a reduction in clonogenicity of around 30-50%, when melanoma cells 
were infected with dnFGFR1-GFP viruses, compared to those cells transduced with 
GFP adenoviruses. Thus, it is suggested that inhibition of the FGFR-1 signalling 
pathway affects also the ability to form clones, presumably due to reduced stimulation of 
growth and survival by surrounding cells (Figure 4.17 and 4.18). 
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Figure 4.18: Results of Clonogenicity Assay, showing three 
different melanoma cell lines GFP versus dnFGFR1-GFP 
infected. Clonogenicity of GFP transduced melanoma cells were 
set as 100% One cell line  tested (VM1) did not form clones, 
when seeded at low density. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.3 Soft Agar Assay 
 
Melanoma cell lines were tested for their anchorage independent growth in three-
dimensional culture. Cells were seeded in 10% RPMI medium including agar. The 
formation of clones was monitored and the number of clones with a diameter above a 
specific threshold (> 20 µm) was calculated. Cells were incubated around one month, 
but adenoviruses are suggested to be diluted out already after three weeks, thus 
fluorescence was reduced significantly. Therefore, small clones were not taken into 
consideration. Results showed significant reduction of anchorage independent 
clonogenicity. Thus, the ability to form clones in soft agar was reduced around 90% in 
three of four melanoma cell lines infected with dnFGFR1-GFP bearing adenoviral 
constructs (Figure 4.19 and 4.20).  
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Figure 4.19: Example of two melanoma cell lines (VM1 and VM48) tested for anchorage independent 
clonogenicity in soft agar. Cells were infected with adenoviruses bearing GFP or dnFGFR1-GFP 
constructs, before seeding. Experiment was done once for all four cell lines, four different areas per well 
were counted. 
 
 
 
Figure 4.20: Results of soft agar assay of all four cell lines tested. Cells were 
infected with adenoviruses (GFP versus dnFGFR1-GFP). 30 000 cells were 
seeded. Melanoma cells infected with GFP adenoviruses were taken as reference 
and set as 100%. 
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4.3.4 In Vivo Tumour Growth 
 
To test FGFR-1 inhibition of melanoma cell lines under in vivo conditions, cells were 
infected with adenoviruses containing GFP versus dnFGFR1-GFP constructs and 
subsequently injected subcutaneously into SCID mice. Tumour growth was monitored 
over several months. The tumour volume was calculated according to the formula ((d12 x 
d2)/2 = tumour size in mm3; d...diameter of tumour in mm; d1 < d2). Mice were sacrificed 
when tumours had reached a certain size (>4000 mm3) or when mice showed signs of 
morbidity (Figure 4.21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21: Tumour growth of melanoma cell line VM1 infected by adenoviruses 
containing GFP versus dnFGFR1-GFP constructs. Following infection, one million cells 
(in 50µl serum free medium) were injected subcutaneously into SCID mice.  
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Tumour growth was reduced to around 50% when the FGFR-1 signalling pathway was 
down-regulated by dnFGFR1-GFP adenoviral infection (Figure 4.21). VM1 melanoma 
cells infected with kdFGFR3 or dnFGFR4-CFP adenoviral constructs did not show a 
reduction in tumour growth. Increased apoptosis, thus programmed cell death, was 
shown by Western Blot analysis (Figure 4.16) in cells tranduced with dnFGFR1-GFP 
constructs, compared to GFP virus infected controls. Overall survival of SCID mice was 
also increased, when dnFGFR1-GFP infected melanoma cells were injected, compared 
to GFP control (Figure 4.22).   
 
 
 
Figure 4.22: Percent survival of SCID mice, when 
melanoma cells transduced with GFP or dnFGFR1-GFP 
constructs were injected. 
  
  
 
 
 
 
 
 
 
 
 
4.4 Cell Biologic Effects of FGF Stimulation 
 
Basic fibroblast growth factor (bFGF or FGF-2) is known to be produced by nearly all 
melanomas in vitro and in vivo but not by normal adult melanocytes, which require 
exogenous FGF-2 for growth. This has been verified by different studies, including this 
one, where all investigated melanoma cell lines showed high FGF-2 expression levels. 
The following experiments showed, that despite endogenous FGF expression, 
exogenous FGF-2 not only increases cell proliferation, but also stimulates cell migration 
and invasion. 
 
83 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23: Four different VM cell lines were incubated with FGF-2 (20 ng/ml). 6000 cells were 
seeded in medium with 10% FCS. The following day, FGF-2 was added at 2x concentration in serum 
free medium, yielding a medium with 5% FCS. Cells were incubated for six days. Controls contained 
no FGFs. A: FGF-2 stimulated growth in all four cell lines tested B: Average growth stimulation of VM 
cell lines, compared to controls containing no FGF-2. Two independent experiments were done in 
duplicates. 
 
 
All four melanoma cell lines incubated with 20 ng/ml FGF-2 proliferated around 30% 
more rapidly than those not stimulated (Figure 4.23). Considering the strong autocrine 
FGF-2 expression of those cell lines, showing up to 150 x higher expression levels 
than primary melanocytes (PM: 1,1; VM21: 25,4; VM1: 58,1; VM24: 150,4; VM48: 6,1 
Relative Expression), these stimulatory effects are quite strong. Those two cell lines 
showing the lowest FGF-2 expression, namely VM48 and VM21, could be more 
strongly stimulated for proliferation than the other two. Proliferation of VM48 cells was 
increased by 50%, despite having 6 x higher FGF-2 expression than primary 
melanocytes. 
 
Those two melanoma cell lines, having the highest and lowest FGF-2 expression 
(VM24 and VM48), were subjected to migration assays. Only those cells, able to 
migrate through the transwell chamber and settle on the bottom of the well, were taken 
into consideration. Three other cell lines were not further investigated, because cells 
did not migrate properly. Migration was stimulated by FGF-2 and FGF-5, reported as an 
oncogenic factor in human glioblastoma (Allerstorfer, Sonvilla et al., 2008), at 
physiological (20 ng/ml) and supra-physiological (each 100 ng/ml) concentrations 
(Figure 4.24).  
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Figure 4.24: Two melanoma cell lines were tested for migration through a porous membrane, 
when stimulated by different concentrations of FGF-2, compared to non-stimulated cells.  
40 000 cells were seeded into a transwell chamber in RPMI containing 4% FBS and incubated 
for 72 hours. Cells which migrated through the porers of the membrane and dropped to the 
bottom of the well were stained by crystal violet and analysed by Lucia Software (Nikon). Two 
independent experiments were done in duplicates. 
 
 
FGF-5 expression was not detected (FGF-5 short) or very weakly expressed (FGF-5 
long) in primary melanocytes, but was up-regulated in many melanoma cell lines. The 
long isoform of FGF-5 was also up-regulated in VM24 cells (37,4) used in this migration 
assay, but was low in VM48  melanoma cells (0,4), as well as in primary melanocytes 
(0,2). Thus, the VM24 cell line showed 187 x higher FGF-5 expression compared to 
primary melanocytes.  
 
Surprisingly, both FGFs showed nearly the same stimulatory effects on migration 
(Figure 4.24 and 4.25). The cell line expressing high levels of FGF-2 and FGF-5, 
thereby stimulating itself in an autocrine manner, showed less stimulatory effects than 
the VM48 cell line having low FGF-2 and FGF-5 expression levels. In comparison, the 
VM24 cell line increased migration by around 20-30% and the VM48 even by up to 
50%. Besides, migration could be further stimulated at higher FGF concentrations (100 
ng/ml each), and resulted in around 2 x higher motility.  
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Figure 4.25: Migration ability was tested by Transwell Chamber Assays, for five VM cell 
lines (VM1; VM48; VM24; VM21 and VM7), at different serum and FGF concentrations. 
Cells migrated for 72 hours. Negative controls (neg.) and media including FGFs contained 
only 4% serum, while positive controls (pos.) contained 10% FCS. FGF concentrations:  
A, 20 ng/ml; B, each 100 ng/ml. One representative experiment with VM24 cells is shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5 Effects of FGF Stimulation and Small Molecule Inhibition on 
FGFR Downstream Signalling 
 
The aim of this part of the study was (A) to stimulate FGFR signalling by FGF-2 for 
identification of downstream regulators in melanoma, and (B) to suppress FGFR 
signalling by small-molecule FGFR inhibitors. FGFR signalling is complex, but main 
signalling is suggested to run over the MAPK-pathway and Akt-pathway, thus we 
focused on those two signalling cascades. The FGFR1-specific inhibitor PD166866 
(Panek, Lu et al., 1998) was generously supplied by Pfizer Global Research and 
Development and the pan-FGFR inhibitor SU5402 (Mohammadi, McMahon et al., 
1997) was obtained from Calbiochem.  
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Figure 4.26: Two melanoma cell lines were stimulated with FGF-2 and FGF-5 (each 50 
ng/ml) for different durations of time (15 min, 60 min and 24 hours). Cells were starved for 
24 hours under serum free conditions, before FGFs were added. Proteins were isolated by 
scraping cells into ice cold PBS and subsequent centrifugation and lysis by addition of lysis 
buffer (LBII).  
 
 
 
Stimulation of FGFR downstream signalling was found after FGF-2/FGF-5 incubation 
for different time periods (Figure 4.26). Both melanoma cell lines investigated, 
displayed autocrine FGF stimulation mainly by FGF-2 up-regulation, shown by qRT-
PCR expression analysis. When treated with a combination of exogenous FGF-2 and 
FGF-5, the VM1 cell line showed increased S6 phosphorylation after 24 hours, while 
VM48 cells displayed increased phosphorylation after 1 hour. Considering endogenous 
FGF-2 and FGF5 expression levels, the VM1 cell line had a 50 fold up-regulation of 
FGF-2 and a 30 fold up-regulation of FGF-5, compared to primary melanocytes. VM48 
cells had only a 5 fold up-regulation of FGF-2, FGF-5 was not detected. Nearly the 
same result was obtained for ERK1/2 phosphorylation. While phosphorylation of 
ERK1/2 took place in VM48 cells already after one hour, in the VM1 cell line 
phosphorylation seems to occur at a later stage.  
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Figure 4.27: Effects of FGF-2 (f2, 20 ng/ml) and “Small Molecule Inhibitor” PD166866 (5 µM) on 
FGFR downstream signalling. Cells were starved for 48 hours in serum free medium. PD166866 was 
added one hour and FGF-2 15 minutes before harvest. Proteins were isolated by scraping cells into 
ice cold PBS, then according to standard protocol.  
 
 
FGFR stimulation by FGF-2 for a short time period of 15 minutes, suggested to be 
sufficient for activation of phosphorylation cascades, showed very weak to no 
stimulation in both melanoma cell lines, considering the phosphorylation of Akt and S6 
and STAT3 (Figure 4.27).  
 
The VL10 cell line was used as positive control, because FGFR downstream signalling 
was described already in this cell line (Fischer, Taylor et al., 2008). The VM48 cell line, 
having low endogenous FGF-2 expression compared to VM1 cells, was more suitable 
for FGF stimulation again. Down-regulation of FGFR signalling by FGFR-1 small-
molecule inhibitor PD166866 was not achieved, as far as VM48 cells are concerned, 
even a weak stimulation was observed. However, prior incubation of PD166866 
prevented subsequent stimulation by FGF-2 incubation, at least in VM48 cells. 
 
Further experiments, focusing on incubation with small-molecule inhibitors PD166866 
and SU5402 for different periods of time (2h and 24h), showed rather unexpected 
results. Instead of inhibiting signalling, the opposite was observed, namely stimulation 
of MAPK- and Akt- signalling pathways (Figure 4.28 and 4.29).  
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Figure 4.28: Three melanoma cell lines were incubated for 2 hours with “Small Molecule 
Inhibitors” SU5402 (20 µM) and PD166866 (20 µM). Cells were incubated in 5% RPMI. 
Proteins were isolated by scraping cells into ice cold PBS, then according to standard 
protocol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.29: Four melanoma cell lines were incubated for 24 hours with 
“Small Molecule Inhibitors” SU5402 (20 µM) and PD166866 (20 µM), in 5% 
RPMI. Proteins were isolated by cell trypsinization, not by scraping into PBS, 
the rest was done according to standard  protocol. 
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4.6 Investigation of the Cell Biologic Significance of the FGFR-4 
Arg/Gly Polymorphism  
 
Recently, a germ line polymorphism in the gene encoding for FGFR-4 was discovered 
(Bange, Prechtl et al., 2002). This single nucleotide polymorphism (SNP) results in a 
change of the amino-acid sequence at codon 388 from glycin to arginine (Gly388 to 
Arg388). It is suggested, by different studies, that the FGFR-4 Arg388 allele positively 
stimulates cancer progression in a variety of tumour types (Bange, Prechtl et al., 2002; 
Falvella, Frullanti et al., 2009; Morimoto, Ozaki et al., 2003; Wang, Stockton et al., 2004; 
Wang, Yu et al., 2008) and is associated with adjuvant therapy resistance in primary 
breast cancer (Thussbas, Nahrig et al., 2006).  
 
The purpose of this part of the thesis was, to evaluate whether the FGFR-4 Arg388 
allele correlated with metastasis in melanoma, and to investigate its effects on 
proliferation and migration. This was achieved (A) by RFLP (Restriction Fragment 
Length Polymorphism) analysis of 41 melanoma cell lines from primary tumours and 
metastases of melanoma and (B) by establishing FGFR-4 Arg388 versus Gly388 
expressing cell lines and investigating their migration and proliferation ability. 
 
 
 
 
 
 
 
 
 
4.6.1 Investigation of the FGFR-4 Arg/Gly388 Polymorphism by RFLP 
Analysis 
 
The FGFR-4  Arg/Gly polymorphism was investigated on the RNA level, thus may not 
necessarily correspond with genomic DNA. The denotations heterozygotous or 
homozygotous are related in this context to expression and not genotype. RNA was 
isolated, cDNA was synthesized and FGFR-4 fragment was amplified by standard RT-
PCR. Afterwards, the amplicon was cleaved with restriction enzyme MspI (Fermentas) 
and fragments were separated by 8.5% PAGE gels (Figure 4.30). 
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                                     VM13               VM18          VM6 
     Arg/Arg           Gly/Gly            Arg/Gly   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.30: Example of RFLP (Restriction 
Fragment Length Polymorphism) analysis 
of three different melanoma cell lines, 
thereby identification of expressed FGFR-4 
(Arg/Gly) variants.  
 
 
Due to the SNP (Single Nucleotid Polymorphism) a second cleavage site is present in 
the Gly-allele producing three fragments: 85 bp; 50 bp; 30 bp. In contrast, the amplicon 
of the Arg-allele is cleaved only once generating two fragments of 115 bp and 50 bp. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 4.31: Correlation of FGFR-4 “Arg” expression with malignant 
tumour progression. (A) Percentage of cell lines, of different origins 
(Primary Tumours; Metastases; Malignant Effusions), expressing specific 
FGFR-4 variants. (B) Total number of cell lines tested for FGFR-4  
Arg/Gly polymorphism. 
 
91 | P a g e  
 
Cell Line Origin Histology Polymorphism Cell Line Origin Histology Polymorphism
Mela PM GG VM-37 Xfoa SC NM GG
VM-10 Jmum PT SSM GG VM-18 Pnjc SC ALM GG
VM-19 Rall PT SSM GG VM-34 Xbne SC Unknown GG
VM-30 Wcre PT SSM GA VM-35 Xdbc SC Unknown GA
VM-36 Xewl PT SSM GG VM-9 Gyk BN SSM GG
VM-44 Xapg PT SSM GG VM-22 Rima BN NM GG
VM-2 Gcrf PT NM AA VM-46 Huma BR NM AA
VM-7 Gtbs PT NM GG VM-47 Host BR NM GG
VM-21 Rhtp PT NM GG VM-48 Kaka BR NM GA
VM-23 Rktj PT NM GG VM-50 Hoin BR NM GG
VM-25 Tpck PT NM GA VM-28 Tmfi BR Unknown GA
VM-32 Wpza PT NM GG VM-41 Ydfr BR Unknown GA
VM-33 Wubi PT NM GA VM-31 Wltj ME NM GG
VM-38 Xiba PT NM AA VM-11 Jtst ME NM GA
VM-5 Grbd LN SSM GA VM-13 Krfm ME NM AA
VM-1 Ftsl/a LN SSM GG VM-16 Myah ME Unknown GA
VM-20 Rgoh LN NM GA VM-3 Gesp ME Unknown AA
VM-4 Glj LN NM GA
VM-6 Gsta LN NM GA
VM-8 Gubs/a LN NM GG
VM-12 Jwmw LN NM GA
VM-14 Lcwc LN NM GA
VM-15 Mjzj LN Unknown GA
VM-17 Nra LN Unknown GG
VM-24 Shtj LN Unknown GG
Co-expression of the “Arg/Gly” allele was found in around 23% of cell lines originating 
from a primary tumour (Figure 4.31 and Table 4.3), in contrast to 46% of cell lines 
derived from metastases. Cell lines expressing only the FGFR-4 “Gly” allele were found 
in 62% of cells originating from primary tumours, but only in around 43% of metastasis 
derived cells, a reduction of around 19%. Considering cell lines originating from 
malignant effusions, only one of five cell lines investigated, was found to be 
“homozygous” for the FGFR-4 “Gly” allele, whereas two of them, were found to be 
homozygous for the FGFR-4 “Arg” allele. Although only five cell lines could be 
investigated, the high prevalence of the “Arg” allele in this late stage of melanoma 
progression is quite impressive. Due to these results, we decided to further investigate 
the effects of the FGFR-4 “Arg” allele on cell proliferation and cell motility, by generating 
stable cell lines ectopically expressing the “Gly” and “Arg” alleles.  
 
 
Table 4.3: Analysis of FGFR-4 Arg/Gly polymorphism by RFLP. List of all 41 melanoma cell lines, 
including primary melanocytes, VM (Vienna Melanoma) numbers, origina and histologyb.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aEstablishment of cell lines from primary tumours (PT), lymph node (LN), subcutaneous (SC), bone (BN), 
brain (BR) metastases, malignant effusions (ME) of malignant melanoma and primary melanocytes (PT), 
from which cDNA was used as control and was obtained from primary culture only. bHistology of the 
primary tumour: ALM, acral lentiginous melanoma; NM, nodular melanoma; SSM, superficial spreading 
melanoma. 
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4.6.2 Generation of FGFR-4 Arg388 versus Gly388 Expressing Cell Lines 
and Investigation of Migration and Proliferation  
 
Two melanoma background cell lines, namely VM27 (GTBS) and VM24 (SHTJ), were 
chosen for the generation of stably expressing FGFR-4 Arg/Gly388 cells. Both cell lines 
displayed low FGFR-4 expression levels and were Gly388 homozygous, according to 
RFLP and qRT-PCR analysis. Cell lines were lipofected with plasmids coding for 
FGFR-4 Arg388 or FGFR-4 Gly388, regulated by a constitutively active promoter 
region, and with an empty control plasmid (pcDNA3). Vectors as well as control DNA 
coded for an antibiotic resistance gene (G418), making the selection procedure 
possible. After lipofection and selection, four clones (A-D) per approach were picked, 
resulting in a total of 24 cell fractions. Subsequently, cDNA was generated from all cell 
lines, which were then analysed by RFLP, qRT-PCR and Immuno-histochemistry 
(Figure 4.32 and 4.33). However, only two FGFR-4 Arg388 cell lines (SHTJ) were 
identified as positive and subjected for proliferation and migration assays. Transfected 
GTBS cells did not deliver any Arg388 positive cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.32: RFLP (A) and qRT-PCR (B) analysis of FGFR-4 Arg/Gly388 transfected GTBS and SHTJ 
cells. Only SHTJ melanoma cells subjected for further analysis are shown. The abbreviations pc/arg/gly 
imply transfected DNA (pc: pcDNA3 control; arg: FGFR-4 Arg388 vector and gly: FGFR-4 Gly388 
vector), while A/B/C/D imply picked clones. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.33: Western Blot analysis of FGFR-4 Arg/Gly388 transfected GTBS and SHTJ cells. Only 
SHTJ melanoma cell lines are shown. Abbreviations A-D imply clone label, blue coloured cell fractions 
were subjected to further cell biological analysis. 
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For investigation of cell biological effects, such as proliferation and migration, 
transfected cell fractions were stratified according to FGFR-4 expression levels, 
analysed by qRT-PCR and Western blot (Figure 4.32 and 4.33). Thus, SHTJ melanoma 
cell lines pcB/argD/glyD and pcC/argA/glyA were compared among each other. 
According to Western Blot analysis, cell lines pcB/argD/glyD seem to have slightly more 
FGFR-4 expression than the others. However, qRT-PCR analysis showed no 
differences in FGFR-4 expression levels. Surprisingly, FGFR-4 expression levels of 
transfected FGFR-4 Arg/Gly388 transfected cells were not significantly higher than 
pcDNA3 controls. Even if exogenous FGFR-4 expression is low, it must be sufficient to 
induce a visible shift in the RFLP analysis (Figure 4.32, A). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.34: Stably expressing FGFR-4 Arg/Gly388 melanoma cells were tested for proliferatory and 
migratory ability. (A) Proliferation Assay, 12 000 cells were seeded and incubated for 6 days in 5% RPMI, 
increase in cell number was measured by Casy Cell Counter (Schärfe). (B) Migration Assay, 40 000 cells 
were seeded into a Transwell Chamber and incubated in 4% RPMI for 72 hours, cells were stained by 
crystal violet afterwards. Control pcDNA3 was used as reference and set as 1. Two independent 
experiments in duplicates were done at least. 
 
 
 
Two cell lines, lipofected with FGFR-4 Arg/Gly388 (ArgA and GlyA), had a two-fold 
increased proliferation rate, compared to those cells transfected with control pcDNA3 
(pcC). However, the other two cell lines (ArgD and GlyD) showed no significant 
difference to their control cell line (pcB). Considering cell migration, ArgD cells were 2.5 
times more motile than GlyD cells, although having the same proliferative ability. ArgA 
and GlyA cell lines had also a 1.5 x increased migratory activity than the control, but 
this effect might be an indirect one caused by the increased proliferation of these two 
clones (Figure 4.34 and 4.35). 
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Figure 4.35: Migration assay, example of two cell lines, namely ArgD versus GlyD. Two independent 
experiments were done in duplicates (1-4). 40 000 cells were seeded into a Transwell Chamber and 
incubated in 4% RPMI for 72 hours, cells that migrated through the membrane and dropped to the 
bottom of the well were stained by crystal violet afterwards. 
 
 
 
 
4.7 Generation of Cell Lines for Inducible Expression of 
Dominant-Negative FGFRs (dnFGFRs) - Using the 
Advanced Tet-Off System 
 
Two melanoma cell lines (KAKA;VM48 and FTSL-A; VM1), that showed high lipofection 
efficiency (>30%), were chosen for the generation of inducible expression clones with 
the Advanced Tet-Off System (Clontech).  
 
In summary, the system consists of a small (22 kDa) transcriptional regulator protein 
TetR (Tet Repressor), also referred as rTA-Advanced (transcriptional activating fusion 
protein) in the modified advanced system, and a TRE (Tet-Response Element) 
sequence prior to a gene of interest. TetR blocks transcription of genes, by binding to 
TRE sequences, only in presence of doxocyclin, a derivate of tetracyclin. A more 
detailed description of the system is given in Clontech manuals (Tet-Off Advanced 
Inducible Gene Expression System User Manual, Clonetech). Melanoma cell lines were 
transfected with a plasmid containing the TetR gene driven by a constitutive promoter 
and an antibiotic resistance gene coding for G418 resistance. Lipofection and selection 
was done according to the standard protocol.  After clones were picked and expanded, 
cells were functionally tested for TetR expression.  
 
 
95 | P a g e  
 
For that purpose, cells were transiently transfected with a plasmid encoding an EGFP 
reporter gene coupled to a Tet Response Element (TRE) acting as promoter. Cells from 
a TetR-expressing clone, were separated into two wells. One sample was incubated 
with doxocyclin (100 ng/ml) while the other was not. The sample including doxocyclin 
should prevent reporter gene expression, which in our case would be EGFP, thus no 
fluorescence should be visible under the microscope (Figure 4.36).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.36: Example of one expanded KAKA (VM48) 
TetR positive clone, tested functionally by suppressing 
EGFP expression due to doxocyclin supplementation. 
Putative TetR expressing KAKA cells were lipofected 
with the plasmid coding for the response element and 
the EGFP gene. Therefore, GFP expression can be only 
considered as transient. Pictures were taken 48 hours 
after addition of doxocyclin. On the left side, the sample 
without doxocyclin and on the right side including 
doxocyclin. 
 
 
 
 
Suppression of EGFP fluorescence in the TetR transfected stable clones by the 
addition of doxocyclin proves functional expression of the TetR protein. Fluorescence 
of transfected cells corresponded with standard lipofection efficiency in this cell line of 
about 30%, thus cells can be seen as stable TetR expressing. In our case, four out of 
six picked clones, were identified as TetR positive (Kaka TetR 1/2/3 and 6). 
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Figure 4.37: Quantification of fluorescent TetR 
positive melanoma cells (KAKA; VM48), with and 
without doxocyclin (100 ng/ml). Cells were counted 
under the microscopy. 
 
 
Fluorescent cells were counted under the microscopy (Figure 4.37), within a defined 
space, and compared with the sample including doxocyclin. Quantification revealed a 
reduction of fluorescent cells, in the sample with doxocyclin, of around 98%. However, 
this does not implement, that expression of the reporter gene (EGFP) is zero in non 
fluorescent cells, there might be a low and invisible expression level. Therefore, 
expression levels of EGFP should be determined by qRT-PCR and Western Blot 
analysis. For further and more accurate quantification of fluorescent cells, one could 
perform FACS (Fluorescence Activated Cell Sorter) analysis. 
 
For generation of stable, inducible expression of a gene of interest (GoI; EGFP and 
dnFGFRs), one has to integrate the GoI, linked to TRE sequence, into the genome. 
Thus, a second transfection and selection procedure was necessary. We decided to use 
the KAKA TetR-2 cell line as background strain. Because the TRE vectors used, did not 
possess a selection marker, they had to be co-lipofected with a selection plasmid. In our 
case, the plasmid for selection contained the puromycin resistance gene with a 
constitutive promoter.  
 
However, only KAKA TetR-2 TRE-EGFP clones could be generated. When cells were 
transfected with dnFGFRs, no clones were formed at all. This might happen due to 
leakiness of the TRE-tight system causing low expression of the gene of interest. 
Combined with suggested cell toxicity of dnFGFRs this could lead to cell death of all 
positive cells. 
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In case of KAKA TetR TRE-EGFP clones, cells were expanded and functionally tested 
again. The second round of lipofection and selection was done without G418, to 
conserve cells, but with doxocyclin to suppress expression of dnFGFRs (P/S, 
Puromycin, Doxocyclin). Therefore, the KAKA TetR-2 background strain was always 
kept in doxocyclin (P/S, G418, Doxocyclin).  
 
For functional testing, the first step was to remove the doxocyclin and look for EGFP 
expression. Only three clones, out of eight, showed EGFP expression (Figure 4.38). 
Surprisingly not all cells were expressing the EGFP protein, but only a small 
subpopulation of about 1-3%. The first suggestion was, that the used cell line KAKA 
TetR2 was contaminated with the normal background cell line (KAKA, VM48), and this 
subpopulation might have overgrown TetR cells. Therefore, the G418 was immediately 
resupplemented. The expanded, “positive”,  cells were monitored by microscopy for 
several days, but no change in subpopulations could be observed.  
 
 
 A                                            B                                           C             
 
 
 
 
 
 
 
 
 
Figure 4.38: KAKA TetR-2 TRE-EGFP “positive clones (A-C), in medium without doxocyclin, after 3 
weeks. Plates were about 90% confluent. Only a subpopulation of around 1-3% were fluorescent. When 
doxocyclin was added, EGFP expression was silenced. Only in clone A background cells were also 
fluorescent, but were only weakly expressing EGFP and not inducible, thus could not be silenced by 
adding doxocyclin. Cells of clone B were expanded and subsequently sorted (FACS), twice. 
 
 
 
Finally, we decided to sort out the fluorescent subpopulation by FACS. However, this 
might be even more difficult for KAKA TetR-2 TRE-dnFGFR cells, because one has to 
turn on expression of putative cell toxic dnFGFRs. Besides, only dnFGFR1 and 
dnFGFR4 are coupled to fluorescent proteins, making FACS possible.  
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Figure 4.39: Expanded KAKA TetR-2 EGFP-B clone, after two rounds of sorting (FACS) and 
subsequent expansion.  
 
Following this, the new established cell line KAKA TetR-2 EGFP-B (Figure 4.39) was 
functionally tested by addition (Figure 4.40 and 4.41) and removal (Figure 4.42 and 
4.43) of doxocyclin. The culture was split into two wells, one was incubated with 
doxocyclin and the other one without.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.40: Expression of GFP was inhibited by addition of doxocyclin to 
cell culture medium. One cell fraction was incubated without doxocyclin 
(A), while the other fraction was incubated  in a medium including 
doxocyclin (B).  
 
 
 
Visible GFP expression was completely lost after around two weeks, monitored by 
microscopy. Additionally, GFP expression intensity was measured by FACS analysis, 
24 days after addition of doxocyclin. Original cell line (KAKA) was used as control, and 
displayed no fluorescence (FL1-H value < 10^1). KAKA TetR-2 TRE-EGFP-B culture 
including doxocyclin (+DOX) had a small second population of cells showing low 
fluorescence intensity (FL1-H value > 10^1  but < 10^2), compared to control cell line.  
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This clearly shows the extent of leakiness. The KAKA TetR-2 TRE-EGFP-B culture 
incubated without doxocyclin (-DOX) can be classified into three cell populations, 
namely a small, non-emitting population, a large population showing average 
fluorescence intensity, and another small population with strong fluorescence, even 
beyond the limit of detection (LoD). It is believed, that expression of the gene of 
interest, in this case GFP,  was immediately shut down, when doxocyclin was added. 
However, because of long persistence of the GFP protein, the fluorescence was visible 
for a longer period (~2 weeks).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.41: Results of FACS analysis, after 24 days. (A) 
KAKA background melanoma cell line, (B) KAKA TetR-2 
TRE-EGFP-B cells incubated with doxocyclin, and (C) 
KAKA TetR-2 TRE-EGFP-B cell fraction incubated without 
doxocyclin. 
 
 
After GFP expression was shut down, it was turned on again by withdrawing 
doxocyclin. Cells were washed before doxocyclin free medium was added. Re-
activation of gene expression was monitored by microscopy, and FACS analysis at the 
end of the experiment. At around one week after doxocyclin deprivation, GFP 
expression reached visible maximum again.  
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Figure 4.42: Activation of GFP expression monitored by 
microscopy.  One cell fraction (A) was always incubated without 
doxocyclin, while in the other fraction (B), doxocyclin was withdrawn 
at day 0, thus GFP expression was activated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.43: FACS analysis verified re-activation of GFP 
expression, done two weeks after doxocyclin deprivation. 
(A) KAKA background melanoma cell line, (B) KAKA 
TetR-2 TRE-EGFP-B cells doxocyclin deprived, and (C) 
KAKA TetR-2 TRE-EGFP-B cell fraction incubated 
always without doxocyclin serving as reference. 
 
 
101 | P a g e  
 
 
5 Discussion 
 
5.1 Expression Analysis of FGFs and FGF-Receptors 
 
The fibroblast growth factor (FGF) signalling network plays a ubiquitous role in normal 
cell growth, survival, differentiation, and angiogenesis, but has also been implicated in 
tumour development. Recent studies have shown that FGF can act synergistically with 
vascular endothelial growth factor (VEGF) to amplify tumour angiogenesis. In addition, 
through inducing tumour cell survival, FGF has the potential to induce chemotherapy 
resistance highlighting that chemotherapy may be more effective when used in 
combination with FGF inhibitor therapy. Furthermore, FGFRs have variable activity in 
promoting angiogenesis, with the FGFR-1 subgroup being associated with tumour 
progression and the FGFR-2 subgroup being associated with either early tumour 
development or decreased tumour progression (Korc & Friesel, 2009). 
 
Considering the status of research on FGF and FGFR expression in cancer, over-
expression of FGFR-1 by gene amplification frequently occurs in breast cancer 
(Jacquemier, Adelaide et al., 1994), while over-expression through translocation was 
reported for FGFR-3 in multiple myeloma (Chesi, Nardini et al., 1997). An activating 
point mutation of FGFR-3 is frequently found in bladder and cervix carcinoma 
(Cappellen, De Oliveira et al., 1999), whereas a constitutively activated form of FGFR-4 
was found in pituitary tumours (Ezzat, Zheng et al., 2002). Recently, glioblastoma and 
NSCLC have been added to the list of malignancies containing mutations in the FGFR 
molecules (Rand, Huang et al., 2005; Zhao, Liu et al., 2005). Apart from changes in 
receptor expression and function, over-expression of FGF ligands has been reported 
for a great variety of human tumours. Elevated expression of FGF-2 was found in body 
fluids of patients with cancers of colon, liver, bladder, head and neck, skin, lung, 
kidney, brain and soft tissue (Brunner, Metz et al., 1994; Nguyen, Grossi et al., 1994; 
Nguyen, Steinberg et al., 1994; Nguyen, Watanabe et al., 1994). But also FGF-3, FGF-
4, and FGF-8, which are normally not expressed to high levels in adult tissues, have 
been found over-expressed in a number of human neoplasms, for instance in Kaposi´s 
sarcoma, and in carcinomas of the breast, prostate, ovary and esophagus (Kiuru-
Kuhlefelt, Sarlomo-Rikala et al., 2000; Valve, Nevalainen et al., 2001; Wagata, Ishizaki 
et al., 1991; Zammit, Coope et al., 2002). 
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In melanoma, several reports have established an oncogenic role of FGF-2 and FGFR-
1 (Becker, Lee et al., 1992; Nesbit, Nesbit et al., 1999; Ozen, Medrano et al., 2004) and 
a correlation between FGFR-4 protein expression and survival of melanoma patients 
has been described (Streit, Mestel et al., 2006; Wang & Becker, 1997). It is known that 
normal melanocytes do not express FGF-2 (Reed, McNutt et al., 1994; Scott, Stoler et 
al., 1991), while all melanomas produce FGF-2 and expression levels seem to increase 
during melanoma progression (al-Alousi, Barnhill et al., 1996; al-Alousi, Carlson et al., 
1996; LaVail, Faktorovich et al., 1991). An autocrine growth stimulatory role for FGF-2 
in melanoma has been clearly established through inhibition of FGF-2 activity by 
intracellular injection of blocking antibodies (Halaban, Kwon et al., 1988; Halaban, 
Langdon et al., 1988a; Halaban, Langdon et al., 1988b) or by suppression of synthesis 
with antisense oligodeoxynucleotides (Becker, Meier et al., 1989).  
 
Inhibition of expression of the FGFR-1, inhibits proliferation in vitro (Becker, Lee et al., 
1992) and in vivo (Wang & Becker, 1997). The presence of dominant negative 
receptors (Yayon, Ma et al., 1997) and the use of aromatic anionic compounds such as 
Suramin, that sequester FGF-2 (Davol, Beitz et al., 1995), have further delineated the 
autocrine role of FGF-2 in melanoma progression. FGF-2 is mitogenic not only for 
melanocytes, but also for fibroblasts and endothelial cells. Thus, it is known that 
melanoma-derived FGF-2 has potential paracrine functions in angiogenesis and 
stromal formation (Nesbit, Nesbit et al., 1999). 
 
In our study we showed, that FGFR-1 and FGFR-4 are highly expressed in nearly all 
melanoma cell lines, while expression levels of FGFR-2 and FGFR-3 were found to be 
significantly lower, thus seem to have less importance in melanoma development. 
Taking non-transformed melanocytes as reference, the expression of FGFR-4 and 
FGFR-2 seems to be up-regulated in nearly all melanoma cell lines, while expression of 
FGFR-1 is maintained on a high level and FGFR-3 stays low. Due to the fact that those 
primary melanocytes used in this study as reference are of embryonic origin, and 
because of the known importance of FGFRs during embryonic development, high 
FGFR-1 expression levels in embryonic melanocytes does not ensure high expression 
in adult “non-transformed” melanocytes. In general, expression levels of all FGFRs and 
isoforms were heterogeneous. Truncated FGFR isoforms, especially those lacking the 
TM-domain, were not detected in around half of melanoma cell lines and are suggested 
to be expressed on a low level.  
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It was shown recently, that around 10% of melanoma tumours harbour mutations in the 
FGFR-2 gene. These novel mutations include three truncating mutations occurring at 
evolutionary conserved residues. Mutations result in receptor loss of function through 
several distinct mechanisms, including loss of ligand binding affinity, impaired receptor 
dimerization, destabilization of the extracellular domains, and reduced kinase activity. 
This study suggests FGFR-2 to even oppose melanoma development and correlates 
with our findings, namely its low-level expression in melanoma cells. Therefore, FGFR-
2 was not subjected to further investigations considering tumour promoting effects. 
Thus, experiments investigating cancer promoting effects of FGFRs focused on FGFR-
1 and FGFR-4, because of significantly higher expression levels. Expression of FGF 
ligands showed that FGF-2 was found to be highly up-regulated in all melanoma cell 
lines (100%) investigated and FGF-5 was up-regulated in the majority (90%). 
Expression of  FGF-18 was found to be up-regulated in 40%, while expression of FGF-
17 and FGF-8 stayed low in all melanoma cell lines. Similar to FGF-Receptors, ligands 
were also expressed in a heterogeneous manner considering investigated cell lines. 
 
Results showing high FGF-2 expression levels in all melanoma cell lines, agree with 
other studies published in recent years. Its importance in tumour angiogenesis, beside 
the more popular VEGF, might also apply for melanoma. Targeting both the FGF and 
VEGF pathways may be more efficient in suppressing melanoma angiogenesis, than 
targeting VEGF alone. Besides, around 90% of melanoma cell lines investigated 
showed FGF-5 up-regulation and about 40% FGF-18 up-regulation. In case of FGF-18, 
expression was also high in primary melanocytes, in contrast to very low FGF-5 
expression. Oncogenic roles of both factors have been described in other tumour types 
already, namely in glioblastoma and colorectal tumours (Allerstorfer, Sonvilla et al., 
2008) and may also have an important role in melanoma development. FGF-5 was 
originally identified by a screening approach for transforming oncogenes (Zhan, Bates 
et al., 1988) and subsequently characterized as a regulator of the hair growth cycle 
(Hebert, Rosenquist et al., 1994; Taniguchi, Harada et al., 2003). Moreover, FGF-5 
affects astroglial properties in vitro (Reuss, Hertel et al., 2000), and shows neurotrophic 
activity in vivo (Ozawa, Suzuki et al., 1998). While murine FGF-5 is widely expressed 
during embryogenesis, it is suggested to be restricted to the central nervous system in 
adult mice (Goldfarb, Bates et al., 1991; Haub, Drucker et al., 1990; Haub & Goldfarb, 
1991). Considering its oncogenic role, it was shown recently, that apoptosis induction 
of glioblastoma (GBM) cell lines by prolonged serum starvation was significantly 
prevented by FGF-5.  
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siRNA-mediated FGF-5 down-modulation reduced GBM cell proliferation, while 
recombinant FGF-5 increased this paramenter preferentially in cell lines with low 
endogenous expression levels. Moreover, tumor cell migration was distinctly stimulated 
by FGF-5 but attenuated by FGF-5 siRNA (Allerstorfer, Sonvilla et al., 2008). Due to its 
known importance in the central nervous system and the neuroectodermal origin of 
melanocytes, the oncogenic role of FGF-5 in melanoma might be expected. Because of 
the high expression levels in melanoma, FGF-5 was also tested for its ability to 
stimulate melanoma cell migration. Migration assays showed, that FGF-5 reached the 
same stimulatory effects on migration like FGF-2, namely up to a 50% increase.  
Considering FGF-18, its expression was shown to be up-regulated in 34/38 colorectal 
tumours and is progressively enhanced during colon carcinogenesis reaching very high 
levels in carcinoma. Moreover, it is suggested that FGF-18 affects both tumour cells 
and tumor microenvironment in a pro-tumourigenic and pro-metastatic way (Sonvilla, 
Allerstorfer et al., 2008). Our expression data suggests the probability of a similar role 
of FGF-18 in a melanoma subpopulation.  
 
 
 
 
 
5.2 Inhibition of FGFR Signalling by Dominant Negative 
Receptor Constructs 
 
The purpose of this study was to evaluate FGF-Receptors as putative therapy targets 
in melanoma. Experiments were done in vitro as well as in vivo by prior adenoviral 
transduction of melanoma cell lines, thereby generating transient dominant-negative 
FGF-Receptor expression. Adenoviruses contained dominant-negative receptor 
constructs under a constitutively active promoter region. Transient, but extensive, 
expression of non-functional FGFRs was suggested to down regulate FGFR mediated 
signalling via dimerization with the endogenous receptors, thus act in a dominant 
negative fashion.  
 
A difficult part was to find appropriate MOIs (Multiplicity Of Infection) for the 
transduction procedure. The aim was to choose appropriate MOI values leading to 
equivalent episomal protein expression of all adenoviral constructs. Investigations 
showed that MOIs up to 5 had no effect on cell proliferation, but an MOI of 30 reduced 
proliferation around 15%.  
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However, the differences in episomal protein expression between the diverse 
adenoviral constructs were enormous, when equal MOIs were used. Therefore, we 
decided to raise MOIs for dnFGFR1-GFP (MOI: 5), kdFGFR3 (MOI: 30), dnFGFR4-
CFP (MOI:30) compared to our GFP control (MOI: 2). Reduced proliferation, caused by 
high MOI values, of kdFGFR3 and dnFGFR4-CFP infected cells had to be considered 
afterwards. Protein expression levels of dnFGFR constructs were still significantly lower 
than those of GFP control. The highest gap was found between kdFGFR3, dnFGFR4-
CFP and GFP control. Expression of dnFGFR4-CFP was visibly lower when monitored 
by fluorescence microscopy. Considering analysis by immune-blotting, protein 
expression of kdFGFR3 (data not shown) and dnFGFR4-CFP was not detected with 
similar exposure time, used for GFP and dnFGFR1-GFP. Expression of dnFGFR1-GFP 
was also found to be reduced, compared to GFP infected cells, but reduction was not 
as strong as for kdFGFR3 and dnFGFR4-CFP expression. 
 
Results of the proliferation or viability assay clearly showed the impact of the FGFR-1 
mediated FGF-signalling pathway on cell proliferation and apoptosis. Although the 
dnFGFR1-GFP protein was shown to be less expressed, it leads to a decrease of cell 
proliferation of around 50%, compared to the GFP control. What`s more, inhibition of 
the FGFR-4 and FGFR-3 mediated pathway, also decreased cell proliferation around 
20-30%, although fluorescence of the dnFGFR4-CFP protein was barely visible and 
both proteins were not detected by Western blot analysis using similar exposure time, 
thus are suggested to be expressed in low amounts. However, cells transfected with 
kdFGFR3 and dnFGFR4-CFP viral constructs were transduced at MOIs of 30. This was 
shown to be anti-proliferative already by the GFP transfected, thus reduced 
proliferation around 15% by the virus itself. Therefore, it is suggested that anti-
proliferative effects of kdFGFR3 and dnFGFR4-GFP transfected cells are much lower 
than 20-30%. MOIs of 5 did not affect cell proliferation when transfected with GFP 
viruses, thus around 50% reduction in proliferation is indeed caused solely by the 
dnFGFR1-GFP protein and its down-regulation of the FGFR-1 signalling pathway.  
 
That all four cell lines investigated showed nearly the same reduction in proliferation, 
might seem surprising. Expression of dnFGFRs was suggested to be cell line specific. 
What could explain the high correlation between those cell lines is that inhibition of the 
FGF-signalling cascade becomes saturated, thus fully blocked, at lower expression 
levels already.  
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Alternatively, one could argue, that decreased proliferation is caused solely by the 
effects of viral infection but not by expression of dnFGFR1. However, virus caused cell 
toxic effects were tested up to MOIs of 60 by transfection with GFP control viruses. As 
already discussed no cell toxic effects were visible at MOI: 5 suggesting that anti-
proliferative effects are solely caused by the expression of dnFGFR1 indeed. 
Furthermore, it was shown that inhibition of the FGFR-1 pathway in melanoma cells 
leads to apoptosis. This was shown either by propidium-iodide staining of dead cell 
subpopulations, by fluorescence microscopy as well as by immune-blotting. Caspase-3 
and PARP1 were both cleaved in dnFGFR1-GFP-infected cells. However, it remains an 
open question whether anti-proliferative effects are mainly induced by apoptosis, or 
also by inhibition of growth stimulatory effects. Thus, cell number can be reduced in two 
ways, either by inducing apoptosis or by decreasing cell division.  
Considering clonogenic assays, melanoma cells were tested for their ability to survive 
and form clones, when seeded at very low density. Reduction in clonogenicity was found 
to be approximately 30-50%, when melanoma cells were infected with dnFGFR1-GFP 
viruses compared to cells transduced with GFP adenoviruses. Because of significant 
reduction of surrounding cells, thus able to stimulate growth and proliferation, it is 
suggested that the FGFR-1 signalling pathway affects also cell-cell contact-independent 
growth and the ability to form clones.  
 
Following this, a similar assay was performed seeding cells in a three-dimensional 
environment, where cells cannot attach to a surface thereby testing anchorage 
independent clonogenicity. This soft agar assay is suggested to resemble some aspects 
of in vivo growth conditions. The assay revealed, that reduction of clonogenicity was 
even strengthened, when cells were forced to grow in an anchorage independent way.  
To verify those results in vivo, tumour growth was tested by a xenotransplantation 
experiment in SCID mice. Melanoma cells were transduced with adenoviruses 
containing dnFGFR or GFP constructs and were then injected subcutaneously. Results 
highly correlated with proliferation and clonogenic assays, reducing tumour growth to 
around 50%. Besides, survival of SCID mice was also shown to be enhanced, when 
xenotransplanted melanoma cells were infected with dnFGFR1-GFP instead of GFP 
control viruses. However, tumour growth was not affected when cells were infected with 
kdFGFR3 or dnFGFR4-CFP viruses.  
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5.3 Cell Biologic Effects of FGF Stimulation 
 
Two fibroblast growth factors, namely FGF-2 and FGF-5 were tested for oncogenic 
effects on melanoma cell lines. The better investigated factor FGF-2 was tested for its 
ability to stimulate proliferation and migration of melanoma cells, while FGF-5 was 
tested only for influencing migration and invasion. Both factors, investigated in this 
study, were shown to be highly up-regulated in all or most melanoma cell lines.  
FGF-2 is a ubiquitous cellular mitogen that is not readily secreted due to the lack of a 
signal peptide sequence (Florkiewicz & Sommer, 1989). Expression of FGF-2 was 
shown to be up-regulated in many human tumours including melanoma. Whereas 
normal human melanocytes do not express FGF-2 (Reed, McNutt et al., 1994; Scott, 
Stoler et al., 1991), some nevi express it (Ahmed, Ueda et al., 1997; Mancianti, Gyorfi 
et al., 1993; Ueda, Funasaka et al., 1994) and virtually all melanomas produce FGF-2, 
with expression levels increasing during tumour progression (al-Alousi, Barnhill et al., 
1996; al-Alousi, Carlson et al., 1996; Albino, Davis et al., 1991). An autocrine growth 
stimulatory role for FGF-2 in melanoma has been clearly established through inhibition 
of FGF-2 activity by intracellular injection of blocking antibodies (Halaban, Kwon et al., 
1988) or by suppression of synthesis with antisense oligodeoxynucleotides (Becker, 
Meier et al., 1989), FGF-2 is mitogenic not only for melanocytes but also for fibroblasts 
and endothelial cells. Thus, melanoma derived FGF-2 has potential paracrine functions 
in angiogenesis and stroma formation (Nesbit, Nesbit et al., 1999). Transient 
expression of FGF-2 in melanocytes, achieved by adenoviral transduction and vector 
based transfection, showed increased proliferation and survival, when injected into 
human skin grafted to mice (Nesbit, Nesbit et al., 1999). 
Considering our study, it was shown, that FGF-2 expression was indeed highly up-
regulated in all melanoma cell lines investigated. More than half of these cell lines, 
namely six out of eleven, showed 100 x increased expression levels compared to 
primary melanocytes. Proliferation was shown to be stimulated up to around 20% in cell 
lines known to have high FGF-2 expression levels, and even up to 40% in cell lines 
with low endogenous expression. Stimulatory effects on migration ranged from around 
20% to 50%, also depending on endogenous expression levels. Expression analysis 
showed FGF-5 up-regulation in around 90% of investigated melanoma cell lines, 
indicating its importance in melanoma.  
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In our study, FGF-5 reached the same stimulatory effects on migration like FGF-2, 
namely up to a 50% increase. These results highly correlate with a recent study, that 
investigated FGF-5 influence on migration of glioblastoma cell lines (Allerstorfer, 
Sonvilla et al., 2008). 
 
5.4 Effects of FGF Stimulation and Small Molecule Inhibition on 
the FGFR Downstream Signalling 
 
Several new targeted drugs against growth factors and/or their receptors have been 
developed successfully during the last years. The anti-angiogenic vascular growth 
factor (VEGF) antibody bevacizumab and the epidermal growth factor receptor (EGFR) 
small-molecule inhibitor erlotininb, have both been approved for different cancer types. 
Patients with the BCR-ABL translocation can be treated with imitinib-mesylate and 
those with amplification of the oncogene ERBB2, also known as HER2, with 
trastuzumab or lapatinib. New technologies give deeper insights in changes that occur 
within individual tumours and how these changes differ between individual tumours. 
With assays to detect these aberrations that are now used to stratify patients for 
treatment, these data sets are now transforming the practice of cancer medicine, as is 
shown by the success of therapies that target distinct molecular events (Chin & Gray, 
2008).  
 
However, many of these targeted therapy approaches, showed activity in patient 
subgroups only, suggesting that cancer cells can evade anticancer effects by activating 
alternative growth and survival pathways. Evidence has accumulated that members of 
the FGF family together with their four FGFRs might be a further valuable target in 
cancer therapy (Fischer, Taylor et al., 2008). The objective of this study was, to show 
that FGFR downstream signalling can be stimulated by FGFs, thus to find downstream 
activators in melanoma, and that the FGFR signalling pathway can be down-regulated 
by addition of small-molecule inhibitors targeting FGFRs specifically. Probably because 
of the fact, that all melanoma cell lines investigated showed up-regulation of FGF-2, 
additional stimulation of the pathway by addition of exogenous FGF-2 was low. 
However, the cell line with lower up-regulation of endogenous FGF-2 clearly showed 
increased phosphorylation of Akt, ERK1/2 and S6. It was also shown, that FGF-2 
stimulation of FGFRs can be prevented by prior incubation with small-molecule inhibitor 
PD166866. In general, all these effects were lower than initially expected, but may be 
explained by high autocrine stimulation of FGF-2.  
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Inhibition of FGFR downstream signalling, by incubation with small-molecule inhibitors, 
was not shown. It seemed, that those FGFR inhibitors used, even stimulated FGFR 
downstream signalling instead of inhibiting. In vitro proliferation assays, not shown in 
this thesis, showed that cells incubated with PD166866 and SU5402 displayed reduced 
growth, and incubation with other clinical approved inhibitors, targeting other key 
players, showed additive and in some cases synergistic effects. FGFR downstream 
regulators, affected by PD166866 and SU5402 inhibition, need to be identified. Other 
putative signalling pathways, that are known to be activated by FGFRs, include PLCγ, 
PKC, Src and Shc pathways. 
 
 
5.5 Cell Biologic Significance of the FGFR-4 Arg/Gly 
Polymorphism 
 
In the human FGFR-4 gene, a coding polymorphism in exon 9 results in an amino acid 
change, namely from glycin to arginine (Gly388Arg), in the transmembrane domain of 
the receptor. The FGFR-4 Arg388 allele may predispose cancer patients to disease 
progression, based on  the reported significant association between FGFR-4 genotype 
and tumour aggressiveness or survival in different cancer types (Bange, Prechtl et al., 
2002; Falvella, Frullanti et al., 2009; Ma, Tsuchiya et al., 2008; Morimoto, Ozaki et al., 
2003; Wang, Stockton et al., 2004; Wang, Yu et al., 2008). However, this association 
was not confirmed in all studies (Becker, Nieters et al., 2003; Jezequel, Campion et al., 
2004). Considering prostate and lung cancer development and progression, recent 
studies seem to agree on the oncogenic role of the FGFR-4 Arg388 allele (Falvella, 
Frullanti et al., 2009; Ma, Tsuchiya et al., 2008; Wang, Yu et al., 2008), but not so in 
other tissue types.  
 
Another study investigating the effects of the FGFR-4 Arg388 allele suggests an 
association with resistance to adjuvant therapy in primary breast cancer. In node-
positive patients, FGFR-4 Arg388 was significantly associated with poor disease-free 
survival and overall survival and seems to be attributable to relatively poor therapy 
response. Patients carrying the Arg388 allele showed only about half as much benefit 
from adjuvant systemic therapy as wild type carriers (Thussbas, Nahrig et al., 2006). 
Considering the status of research in melanoma, the FGFR-4 Arg388 allele correlated 
with tumour thickness. However, only FGFR-4 protein expression correlated with 
survival of patients (Streit, Mestel et al., 2006). 
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Our results suggest, that the Arg388 allele has a significant promoting influence on 
melanoma progression, which is achieved not by stimulating growth, but by stimulating 
migration and invasion. Increased migration ability would also explain high prevalence 
of the allele in metastatic samples and samples of malignant effusions, indicating late 
clinical stage. Because of improvements in early tumour diagnostics and melanoma 
resection, it was not possible to analyse more samples of late stage malignant 
effusions. These findings also correlate with a study (Bange, Prechtl et al., 2002), 
which investigated migratory effects of the Arg388 allele on several mammary 
carcinoma cell lines. It was shown there, that mammary tumour cells expressing FGFR-
4 Arg388 exhibited increased motility relative to cells expressing the FGFR-4 Gly388 
isotype. What`s more, the Arg388 allele was associated with early lymph node 
metastasis and advanced tumour-node-metastasis of colon cancer patients and a 
significantly reduced disease-free survival time in breast cancer patients.  
 
 
5.6 The Advanced Tet-Off System in Melanoma Cell Lines 
 
Two melanoma cell lines, showing high lipofection efficiency (>30%), were chosen for 
the generation of inducible dnFGFR expression. This was done by using the Advanced 
Tet-Off System (Clontech), described by the company as reliable and tight, and was 
already briefly explained in chapter 3 (Results). It was shown however, that the system 
is still leaky, at least as far as melanoma cell lines are concerned. Generation of stably 
TetR expressing cell lines was achieved, but subsequent transfection with TRE-
dnFGFR plasmids yielded no clones, apart from EGFP controls. It was shown, by using 
FACS analysis, that the system still expressed EGFP when actually silenced by 
doxocyclin. However, the fact that no TetR TRE-dnFGFR clones were obtained, further 
strengthens the acceptance of FGFRs as being cell toxic. This observation could be 
made also, when melanoma cell lines were transfected with plasmids expressing 
dnFGFR constructs from constitutively active promoters. Stable GFP controls were 
obtained from several cell lines, but not a single clone expressing dnFGFRs. 
 
The system itself is actually very expedient, especially to avoid the MOI discussion 
when cells are infected by adenoviruses to allow transient expression of the gene of 
interest. However, the leakiness of the system makes it only useful for genes less cell 
toxic or those stimulating cell growth and viability instead. For instance, it would be 
reasonable to further investigate the FGFR-4 Arg/Gly388 polymorphism, suggested to 
stimulate growth and migration. 
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6.3 Abbreviations 
 
 
APS - Ammonium Persulfate 
BSA - Bovine Serum Albumin 
CFP - Cyan Fluorescent Protein 
DEPC - Diethylpyrocarbonate 
DMSO - Dimethylsulfoxid 
DOX - Doxocyclin 
DTT - Dithiothreitol 
ECM - Extra Cellular Matrix  
EDTA - Ethylendiaminetetraacetic Acid 
EGF - Epithelial Growth Factor 
EGFR - Epithelial Growth Factor Receptors 
ERK - Extracellular Signalregulated Kinase 
EtOH - Ethanol 
FBS - Fetal Bovine Serum 
FGF - Fibroblast Growth Factor 
FGF-BP - FGF Binding Protein 
FGFR - Fibroblast Growth Factor Receptors 
FRS2 - Fibroblast Growth Factor Receptor Substrate 2 
GFP/EGFP - Green Fluorescent Protein/Enhanced Green Fluorescent Protein 
GOI - Gene Of Interest 
HBS - Heparin Binding Site 
HLGAG - Heparin-like Glycosaminoglycan 
HRP - Horseradish Peroxidaase 
ICH - Immunohistochemistry 
IRES - Internal Ribosomal Entry Site 
MAPK - Mitogen Activated Protein Kinase 
MeOH - Methanol 
MOI - Multiplicity of Infection 
o/n - Overnight 
P/S - Penecilin/Streptomycin 
PAGE - Polyacrylamide Gelelectrophoresis 
PBS - Phophate Buffered Saline 
PFA - Paraformaldehyd 
PVDF - Polyvinylidenefluoride 
Rb - Retinoblastoma 
ROS - Reactive Oxygen Species 
RPMI - Roswell Park Memorial Institute  
RT - Room Temperature 
SCID - Severe Combined Immunodeficiency 
SDS - Sodium Dodecyl Sulfate 
STET - Sodiumchloride Tris EDTA Triton X-100 Buffer Solution 
T/E - Trypsin/EDTA 
TBE - Tris/Borate/EDTA 
TBS - Tris Buffered Saline 
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TE - Tris EDTA 
TEMED - N,N,N´,N´-Tetramethylethylenediamine 
Tris - Trishydroxymethyl Aminomethane 
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